<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83004</article-id><article-id pub-id-type="doi">10.7554/eLife.83004</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Polycomb repressive complex 1.1 coordinates homeostatic and emergency myelopoiesis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-292006"><name><surname>Nakajima-Takagi</surname><given-names>Yaeko</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2341-2409</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292007"><name><surname>Oshima</surname><given-names>Motohiko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292008"><name><surname>Takano</surname><given-names>Junichiro</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292009"><name><surname>Koide</surname><given-names>Shuhei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292010"><name><surname>Itokawa</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292011"><name><surname>Uemura</surname><given-names>Shun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1520-6808</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292012"><name><surname>Yamashita</surname><given-names>Masayuki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9459-4329</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292013"><name><surname>Andoh</surname><given-names>Shohei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292014"><name><surname>Aoyama</surname><given-names>Kazumasa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292015"><name><surname>Isshiki</surname><given-names>Yusuke</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292016"><name><surname>Shinoda</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41083"><name><surname>Saraya</surname><given-names>Atsunori</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292017"><name><surname>Arai</surname><given-names>Fumio</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292018"><name><surname>Yamaguchi</surname><given-names>Kiyoshi</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292032"><name><surname>Furukawa</surname><given-names>Yoichi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0462-8631</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-67058"><name><surname>Koseki</surname><given-names>Haruhiko</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8424-5854</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292020"><name><surname>Ikawa</surname><given-names>Tomokatsu</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-40476"><name><surname>Iwama</surname><given-names>Atsushi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9410-8992</contrib-id><email>03aiwama@ims.u-tokyo.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mb6s476</institution-id><institution>Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Yokohama</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01hjzeq58</institution-id><institution>Department of Cellular and Molecular Medicine, Chiba University</institution></institution-wrap><addr-line><named-content content-type="city">Chiba</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Department of Stem Cell Biology and Medicine, Kyushu University</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Division of Clinical Genome Research,Advanced Clinical Research Center, The Institute of Medical Science, University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05sj3n476</institution-id><institution>Division of Immunobiology, Research Institute for Biomedical Sciences, Tokyo University of Science</institution></institution-wrap><addr-line><named-content content-type="city">Chiba</named-content></addr-line><country>Japan</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Laboratoty of Cellular and Molecular Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>06</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83004</elocation-id><history><date date-type="received" iso-8601-date="2022-08-26"><day>26</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-06-01"><day>01</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-09-08"><day>08</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.07.507016"/></event></pub-history><permissions><copyright-statement>© 2023, Nakajima-Takagi et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Nakajima-Takagi et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83004-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83004-figures-v2.pdf"/><abstract><p>Polycomb repressive complex (PRC) 1 regulates stem cell fate by mediating mono-ubiquitination of histone H2A at lysine 119. While canonical PRC1 is critical for hematopoietic stem and progenitor cell (HSPC) maintenance, the role of non-canonical PRC1 in hematopoiesis remains elusive. PRC1.1, a non-canonical PRC1, consists of PCGF1, RING1B, KDM2B, and BCOR. We recently showed that PRC1.1 insufficiency induced by the loss of PCGF1 or BCOR causes myeloid-biased hematopoiesis and promotes transformation of hematopoietic cells in mice. Here we show that PRC1.1 serves as an epigenetic switch that coordinates homeostatic and emergency hematopoiesis. PRC1.1 maintains balanced output of steady-state hematopoiesis by restricting C/EBPα-dependent precocious myeloid differentiation of HSPCs and the HOXA9- and β-catenin-driven self-renewing network in myeloid progenitors. Upon regeneration, PRC1.1 is transiently inhibited to facilitate formation of granulocyte-macrophage progenitor (GMP) clusters, thereby promoting emergency myelopoiesis. Moreover, constitutive inactivation of PRC1.1 results in unchecked expansion of GMPs and eventual transformation. Collectively, our results define PRC1.1 as a novel critical regulator of emergency myelopoiesis, dysregulation of which leads to myeloid transformation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>hematopoietic stem</kwd><kwd>progenitor cell</kwd><kwd>polycomb repressive complex 1.1</kwd><kwd>myelopoiesis</kwd><kwd>emergency myelopoiesis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>19H05653</award-id><principal-award-recipient><name><surname>Iwama</surname><given-names>Atsushi</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>20K08728</award-id><principal-award-recipient><name><surname>Nakajima-Takagi</surname><given-names>Yaeko</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>19H05746</award-id><principal-award-recipient><name><surname>Iwama</surname><given-names>Atsushi</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>21zf0127003h0001</award-id><principal-award-recipient><name><surname>Iwama</surname><given-names>Atsushi</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP223fa627001</award-id><principal-award-recipient><name><surname>Iwama</surname><given-names>Atsushi</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Polycomb repressive complex 1.1 restricts precocious myeloid differentiation of hematopoietic stem/progenitor cells and expansion of myeloid progenitors, thereby serving as a gatekeeper of emergency myelopoiesis and myeloid transformation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>While lifelong hematopoiesis is considered driven by hematopoietic stem cells (HSCs) (<xref ref-type="bibr" rid="bib47">Sawai et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Säwen et al., 2018</xref>), recent evidence pointed out a major role for multipotent progenitors (MPPs) and lineage-committed progenitors in hematopoiesis (<xref ref-type="bibr" rid="bib11">Busch et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Sun et al., 2014</xref>). Hematopoietic stem and progenitor cells (HSPCs) are highly responsive to various stresses such as infection, inflammation, and myeloablation (<xref ref-type="bibr" rid="bib58">Trumpp et al., 2010</xref>; <xref ref-type="bibr" rid="bib66">Zhao and Baltimore, 2015</xref>), which facilitate myelopoiesis by activating HSPCs to undergo precocious myeloid differentiation and transiently amplifying myeloid progenitors that rapidly differentiate into mature myeloid cells (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Pietras et al., 2016</xref>). This reprogramming of HSPCs, termed ‘emergency myelopoiesis,’ serves to immediately replenish mature myeloid cells to control infection and regeneration (<xref ref-type="bibr" rid="bib32">Manz and Boettcher, 2014</xref>). Recent evidence further suggested that uncontrolled activation of the myeloid regeneration programs results in the development of chronic inflammatory diseases and hematological malignancies (<xref ref-type="bibr" rid="bib12">Chiba et al., 2018</xref>; <xref ref-type="bibr" rid="bib66">Zhao and Baltimore, 2015</xref>). Emergency myelopoiesis is driven via activation of key myeloid transcriptional networks at the HSPC and myeloid progenitor cell levels (<xref ref-type="bibr" rid="bib44">Rosenbauer and Tenen, 2007</xref>). However, the epigenetic regulatory mechanisms governing emergency myelopoiesis remained largely unknown.</p><p>Polycomb group (PcG) proteins are the key epigenetic regulators of a variety of biological processes (<xref ref-type="bibr" rid="bib43">Piunti and Shilatifard, 2021</xref>). They comprise the multiprotein complexes, polycomb repressive complex (PRC) 1 and PRC2, which establish and maintain the transcriptional repression through histone modifications. PRC1 and PRC2 add mono-ubiquitination at lysine 119 of histone H2A (H2AK119ub) and mono-, di-, and tri-methylation at lysine 27 of histone H3 (H3K27me1/me2/me3), respectively, and cooperatively repress transcription (<xref ref-type="bibr" rid="bib8">Blackledge et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Iwama, 2017</xref>). PRC1 complexes are divided into subgroups (PRC1.1 to PRC1.6) according to the subtype of the Polycomb group ring finger (PCGF) subunits (PCGF1-6). PCGF2/MEL18 and PCGF4/BMI1 act as components of canonical PRC1 (PRC1.2 and 1.4, respectively) that are recruited to its target sites in a manner dependent on H3K27me3, whereas the others (PCGF1, 3, 5, and 6) constitute non-canonical PRC1 (PRC1.1, PRC1.3, PRC1.5, and PRC1.6, respectively) that are recruited independently of H3K27me3 (<xref ref-type="bibr" rid="bib7">Blackledge et al., 2014</xref>; <xref ref-type="bibr" rid="bib17">Gao et al., 2012</xref>; <xref ref-type="bibr" rid="bib60">Wang et al., 2004</xref>).</p><p>PCGF4/BMI1-containing canonical PRC1 (PRC1.4) has been characterized for its role in maintaining self-renewal capacity and multipotency of HSCs (<xref ref-type="bibr" rid="bib46">Sashida and Iwama, 2012</xref>). We and others have reported that BMI1 transcriptionally represses the loci for <italic>CDKN2A</italic> and developmental regulator genes (e.g., B cell regulators) to maintain self-renewal capacity and multipotency of HSPCs (<xref ref-type="bibr" rid="bib25">Iwama et al., 2004</xref>; <xref ref-type="bibr" rid="bib38">Oguro et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Park et al., 2003</xref>). We also reported that PCGF5-containing PRC1.5 regulates global levels of H2AK119ub, but is dispensable for HSPC function (<xref ref-type="bibr" rid="bib52">Si et al., 2016</xref>). On the other hand, we and others recently showed that PRC1.1 components, PCGF1, KDM2B, and BCOR, maintain normal hematopoiesis and suppress malignant transformation of hematopoietic cells (<xref ref-type="bibr" rid="bib2">Andricovich et al., 2016</xref>; <xref ref-type="bibr" rid="bib24">Isshiki et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>). PRC1.1 consists of PCGF1, RING1A/B, KDM2B, and BCOR or BCLRL1. KDM2B binds to non-methylated CpG islands through its DNA-binding domain, thereby recruiting other PRC1.1 components (<xref ref-type="bibr" rid="bib15">Farcas et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">He et al., 2013</xref>). PCGF1 was found to restrict the proliferative capacity of myeloid progenitor cells by downregulating <italic>Hoxa</italic> family genes in in vitro knockdown experiments (<xref ref-type="bibr" rid="bib45">Ross et al., 2012</xref>). Correspondingly, we demonstrated that Pcgf1 loss induces myeloid-biased hematopoiesis and promotes JAK2V617F-induced myelofibrosis in mice (<xref ref-type="bibr" rid="bib50">Shinoda et al., 2022</xref>). Bcor loss also showed myeloid-biased hematopoiesis and promoted the initiation and progression of myelodysplastic syndrome in collaboration with Tet2 loss (<xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>). However, detailed analysis of the role for PRC1.1 in hematopoiesis, especially in the context of hematopoietic regeneration and emergency myelopoiesis, has not yet been reported.</p><p>Here, we analyzed the murine hematopoiesis in the absence of PCGF1 and uncovered critical roles of PCGF1-containing PRC1.1 in homeostatic, emergency, and malignant hematopoiesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>PCGF1 restricts myeloid commitment of HSPCs</title><p>To understand the function of PCGF1 in hematopoiesis, we crossed <italic>Pcgf1<sup>fl</sup></italic> mice, in which exons 2–7 are floxed (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), with <italic>Rosa26::Cre-ERT2</italic> (<italic>Rosa26<sup>CreERT</sup></italic>) mice (<italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic>). To delete <italic>Pcgf1</italic> specifically in hematopoietic cells, we transplanted bone marrow (BM) cells from <italic>Rosa26<sup>CreERT</sup></italic> control and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> CD45.2 mice into lethally irradiated CD45.1 recipient mice and deleted <italic>Pcgf1</italic> by intraperitoneal injection of tamoxifen (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). We confirmed the efficient deletion of <italic>Pcgf1</italic> in donor-derived hematopoietic cells from the peripheral blood (PB) by genomic PCR (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). RT-qPCR confirmed the significant reduction of <italic>Pcgf1</italic> mRNA lacking exons 2–7 in donor-derived BM Lineage marker<sup>–</sup>Sca-1<sup>+</sup>c-Kit<sup>+</sup> (LSK) HSPCs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). We hereafter refer to the recipient mice reconstituted with <italic>Rosa26<sup>CreERT</sup></italic> control and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> cells treated with tamoxifen as control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice, respectively.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>PCGF1 regulates myelopoiesis but not self-renewal of hematopoietic stem and progenitor cells (HSPCs).</title><p>(<bold>A</bold>) Strategy for analyzing <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic cells. Total bone marrow (BM) cells (5 × 10<sup>6</sup>) from <italic>Rosa26<sup>CreERT</sup></italic> and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> were transplanted into lethally irradiated CD45.1 recipient mice. <italic>Pcgf1</italic> was deleted by intraperitoneal injections of tamoxifen at 4 wk post-transplantation. (<bold>B</bold>) The proportions of Mac-1<sup>+</sup> and/or Gr-1<sup>+</sup> myeloid cells, B220<sup>+</sup> B cells, and CD4<sup>+</sup> or CD8<sup>+</sup> T cells among CD45.2<sup>+</sup> donor-derived hematopoietic cells in the peripheral blood (PB) from control (n = 9) and <italic>Pcgf1<sup>Δ/Δ</sup></italic> (n = 14) mice. (<bold>C</bold>) Absolute numbers of total BM cells, hematopoietic stem cells (HSCs), multipotent progenitors (MPPs), myeloid progenitors, and CLPs (ALP and BLP) in a unilateral pair of femur and tibia 4 wk after the tamoxifen injection (n = 4–5). (<bold>D</bold>) Cell cycle status of CD34<sup>–</sup>LSK HSCs and CD34<sup>+</sup>LSK MPPs assessed by Ki67 and 7-AAD staining 4 wk after the tamoxifen injection. (<bold>E</bold>) In vivo limiting dilution assay. Limiting numbers of BM cells (1 × 10<sup>4</sup>, 4 × 10<sup>4</sup>, 8 × 10<sup>4</sup>, and 2 × 10<sup>5</sup>) isolated from BM of primary recipients (control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice after transplantation) were transplanted into sublethally irradiated secondary recipient mice with 2 × 10<sup>5</sup> of competitor CD45.1 BM cells (n = 5 each). Due to the low contribution of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs to B cells, mice with chimerism of donor myeloid and T cells more than 1% in the PB at 16 wk after transplantation were considered to be engrafted successfully, and the others were defined as non-engrafted mice. The frequencies of HSPCs that contributed to both myeloid and T cells are indicated. (<bold>F</bold>) Strategy for analyzing <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic cells. Total BM cells (2 × 10<sup>6</sup>) from <italic>Rosa26<sup>CreERT</sup></italic> and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> CD45.2 mice were transplanted into lethally irradiated CD45.1 recipient mice with the same number of competitor CD45.1 BM cells. <italic>Pcgf1</italic> was deleted by intraperitoneal injections of tamoxifen at 4 wk post-transplantation. Secondary transplantation was performed using 5 × 10<sup>6</sup> total BM cells from primary recipients at 4 mo post-intraperitoneal injections of tamoxifen. (<bold>G</bold>) The chimerism of CD45.2 donor cells in PB CD45<sup>+</sup> leukocytes, Mac-1<sup>+</sup> and/or Gr1<sup>+</sup> myeloid cells, B220<sup>+</sup> B cells, and CD4<sup>+</sup> or CD8<sup>+</sup> T cells in control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice (n = 6 each) after the tamoxifen injection. (<bold>H</bold>) The chimerism of CD45.2 donor-derived cells in BM 4 wk after the tamoxifen injection (n = 5). (<bold>I</bold>) Absolute numbers of CD45.1 and CD45.2 total BM cells, HSCs, MPPs, myeloid progenitors, and Mac-1<sup>+</sup> mature myeloid cells in a unilateral pair of femur and tibia 4 wk after the tamoxifen injection (n = 5). Statistical significance is based on the overall number of cells. (<bold>J</bold>) The chimerism of CD45.2 donor-derived cells in PB in primary (n = 3 each) and secondary (n = 4–5) transplantation. Data are shown as the mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by the Student’s <italic>t</italic>-test. Each symbol is derived from an individual mouse. A representative of more than two independent experiments is shown.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Targeting of the <italic>Pcgf1</italic> gene in the mouse hematopoietic system.</title><p>(<bold>A</bold>) Gene targeting strategy for the <italic>Pcgf1</italic> gene. (<bold>B</bold>) Strategy for analyzing hematopoietic cells with conditional knockout alleles for <italic>Pcgf1</italic>. Total bone marrow (BM) cells from <italic>Rosa26<sup>CreERT</sup></italic> control and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> CD45.2 mice were transplanted into lethally irradiated CD45.1 recipient mice. After engraftment, <italic>Pcgf1</italic> was deleted by intraperitoneal injections of tamoxifen at 4 wk post-transplantation. (<bold>C</bold>) Efficient deletion of <italic>Pcgf1</italic> exons 2–7 detected by genomic PCR in PB CD45.2<sup>+</sup> hematopoietic cells from recipient mice repopulated with <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> BM cells 4 wk after the tamoxifen treatment. Floxed, floxed <italic>Pcgf1</italic> allele; Δ, floxed <italic>Pcgf1</italic> allele after the removal of exons 2–7 by Cre recombinase. (<bold>D</bold>) Quantitative RT-PCR analysis of <italic>Pcgf1</italic> in BM LSK hematopoietic stem and progenitor cell (HSPCs). <italic>Hprt1</italic> was used to normalize the amount of input RNA. Data are shown as the mean ± SEM (n = 3). The significance of differences relative to control is shown. ***p&lt;0.001 by the Student’s <italic>t</italic>-test.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Uncropped gel images of <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig1-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Accumulation of myeloid cells in <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice.</title><p>(<bold>A</bold>) White blood cell (WBC), hemoglobin (Hb), and platelet (PLT) counts in the peripheral blood (PB) from control (n = 9) and <italic>Pcgf1<sup>Δ/Δ</sup></italic> (n = 14) mice. (<bold>B</bold>) Absolute numbers of Mac-1<sup>+</sup> and/or Gr-1<sup>+</sup> myeloid cells, B220<sup>+</sup> B cells, and CD4<sup>+</sup> or CD8<sup>+</sup> T cells 1 and 6 mo after the tamoxifen injection. (<bold>C</bold>) Representative flow cytometric profiles of bone marrow (BM), spleen, and thymus of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice 1 mo after the tamoxifen injection. The percentages of gated populations over parental populations are indicated. (<bold>D</bold>) Absolute numbers of total cells, Mac1<sup>+</sup> myeloid cells, Mac1<sup>+</sup>Ly6G<sup>+</sup> neutrophiles, Mac1<sup>+</sup>Ly6C<sup>+</sup>Ly6C<sup>–</sup> monocytes, and Mac1<sup>+</sup>F4/80<sup>+</sup> macrophages in the BM and spleen (n = 5 each) 1 mo after the tamoxifen injection. (<bold>E</bold>) Histology of the BM from control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice 1 mo after the tamoxifen injection observed by hematoxylin-eosin staining. (<bold>F</bold>) Absolute numbers of total cells, LSK cells, and myeloid progenitors in the spleen (n = 5 each) 1 mo after the tamoxifen injection. Data are shown as the mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by the Student’s <italic>t</italic>-test.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig1-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Flow cytometric profiles of <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic stem and progenitor cells (HSPCs) and lymphoid progenitors.</title><p>(<bold>A, B</bold>) Representative flow cytometric profiles of bone marrow (BM) HSPCs (<bold>A</bold>) and lymphoid progenitors (<bold>B</bold>) of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice 1 mo after the tamoxifen injection. (<bold>C</bold>) Representative flow cytometric profiles of spleen HSPCs of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice 1 mo after the tamoxifen injection. The percentages of gated populations over parental populations are indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Growth and differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic stem cells (HSCs) in culture.</title><p>(<bold>A</bold>) Growth of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSCs in culture. Cells were cultured in triplicate under HSC (SCF + TPO) and myeloid (SCF + TPO + IL-3 + GM-CSF) culture conditions (n = 3 each). Data are shown as the mean ± SEM. (<bold>B</bold>) Limiting dilution assays of B and T cell differentiation. HSCs from control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice were cocultured with TSt-4 (B cells) or TSt-4/DLL1 (T cells) stromal cells, and the generation of CD19<sup>+</sup> B cells or Thy1.2<sup>+</sup> T cells in each well was detected by flow cytometry after 28 d of coculture (n = 8 each). The calculated frequencies are indicated inside of the plots. Data are shown as the mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by the Student’s <italic>t</italic>-test.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1—figure supplement 4—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig1-figsupp4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig1-figsupp4-v2.tif"/></fig></fig-group><p><italic>Pcgf1<sup>Δ/Δ</sup></italic> mice exhibited mild anemia and leukopenia, which was mainly attributed to the reduction in B cell numbers (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>). Myeloid cell numbers in PB were relatively maintained and their proportion increased over time in <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). While BM cellularity was comparable between control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice, Mac1<sup>+</sup> mature myeloid cells were increased at the expense of B cells in <italic>Pcgf1<sup>Δ/Δ</sup></italic> BM and spleen (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C–E</xref>). Monocytes but not neutrophils or F4/80<sup>+</sup> macrophages significantly increased in <italic>Pcgf1<sup>Δ/Δ</sup></italic> BM while both neutrophils and monocytes significantly increased in <italic>Pcgf1<sup>Δ/Δ</sup></italic> spleen (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C and D</xref>). These findings indicate that <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs generate more mature myeloid cells than the control without showing evident differentiation block. Among the committed progenitor cells, the numbers of granulocyte-macrophage progenitors (GMPs) were significantly increased in <italic>Pcgf1<sup>Δ/Δ</sup></italic> BM, whereas those of megakaryocyte-erythroid progenitors (MEPs), pre- and pro-B cells, all-lymphoid progenitors (ALPs) and B-cell-biased lymphoid progenitors (BLPs) were decreased (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>, and <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>). Of interest, <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice showed reduction in the numbers of HSCs and all subsets of MPPs in BM (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). The reduction in the HSPC pool size was accompanied by decreased cells in cycling phases in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (CD34<sup>–</sup> and CD34<sup>+</sup> LSK cells) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Despite the reduction in phenotypic HSPCs, limiting dilution assays with competitive BM transplantation revealed that the numbers of HSPCs that established long-term repopulation of myeloid and T cells (B cells were excluded due to the low contribution of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs to B cells, see below) were comparable between control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> BM (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Extramedullary hematopoiesis was evident in the <italic>Pcgf1<sup>Δ/Δ</sup></italic> spleen, as judged by markedly increased numbers of LSK HSPCs, GMPs, and mature myeloid cells including monocytes and neutrophils (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C, D, and F</xref> and <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C</xref>). Differentiation of thymocytes in the <italic>Pcgf1<sup>Δ/Δ</sup></italic> thymus was largely normal (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>).</p><p>To further evaluate the role of PCGF1 in hematopoiesis, we transplanted BM cells with the same number of CD45.1 wild-type (WT) competitor cells (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). In this competitive setting, only a mild decrease was detected in the overall chimerism of CD45.2<sup>+</sup> <italic>Pcgf1<sup>Δ/Δ</sup></italic> cells in PB (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). In contrast, the chimerism of <italic>Pcgf1<sup>Δ/Δ</sup></italic> cells in myeloid cells (Mac-1<sup>+</sup> and/or Gr1<sup>+</sup>) was markedly increased while that in B cell lineage (B220<sup>+</sup>) was decreased (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). In BM, <italic>Pcgf1<sup>Δ/Δ</sup></italic> cells outcompeted the competitor cells in the myeloid lineage compartments from the common myeloid progenitor (CMP) stage (<xref ref-type="fig" rid="fig1">Figure 1H</xref>). Since <italic>Pcgf1<sup>Δ/Δ</sup></italic> cell showed reductions in the numbers of HSCs and MPPs in a non-competitive setting (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), we examined the absolute numbers of test and competitor cells in this competitive repopulation. Of interest, the competitive <italic>Pcgf1<sup>Δ/Δ</sup></italic> recipients also exhibit similar changes in BM hematopoietic cell numbers. Both CD45.2<sup>+</sup> <italic>Pcgf1<sup>Δ/Δ</sup></italic> and CD45.1<sup>+</sup> WT cells were depleted in HSPC fractions in <italic>Pcgf1<sup>Δ/Δ</sup></italic> recipients, while the total numbers of myeloid progenitors and mature myeloid cells were maintained or rather increased (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). These findings suggest that <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic cells suppress expansion of both <italic>Pcgf1<sup>Δ/Δ</sup></italic> and co-existing WT HSPCs through non-autonomous mechanisms. It is possible that accumulating <italic>Pcgf1<sup>Δ/Δ</sup></italic> mature myeloid cells produce inflammatory cytokines that are suppressive to HSPCs. The underlying mechanism is an intriguing issue to be analyzed. To evaluate the impact of PCGF1 loss on long-term hematopoiesis, we harvested BM cells from primary recipient mice 4 mo after tamoxifen injection and transplanted them into secondary recipients. <italic>Pcgf1<sup>Δ/Δ</sup></italic> cells reproduced the myeloid-biased hematopoiesis in secondary recipients (<xref ref-type="fig" rid="fig1">Figure 1J</xref>).</p><p>We next evaluated the capacity of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSCs to differentiate to myeloid and lymphoid cells in culture. <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSCs displayed slower population doubling under HSPC-expanding culture conditions (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>), which is in good agreement with fewer cycling <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Nevertheless, <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSCs showed better population doubling than control cells under myeloid culture conditions (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). On the other hand, limiting dilution assays using a co-culture system with TSt-4 stromal cells (<xref ref-type="bibr" rid="bib33">Masuda et al., 2005</xref>) revealed that the capacity of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSCs to produce B and T cells was declined by two- and fivefold, respectively, compared to the control (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>). The discrepancy in T cell production between in vitro and in vivo may be due to the compensatory expansion of T cells in the thymus. These results indicate that PCGF1 loss enhances myelopoiesis at the expense of lymphopoiesis. These phenotypes were similar to those of mice expressing a carboxyl-terminal truncated BCOR that cannot interact with PCGF1 (<xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>).</p></sec><sec id="s2-2"><title>PCGF1 inhibits precocious myeloid commitment of HSPCs through repression of C/EBPα, which is critical for balanced output of HSPCs</title><p>To clarify the molecular mechanisms underlying myeloid-biased differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs, we performed RNA sequence (RNA-seq) analysis of HSPCs from mice 4 wk after the tamoxifen injection. Principal component analysis (PCA) showed shifts of the transcriptomic profiles of <italic>Pcgf1<sup>Δ/Δ</sup></italic> MPP2 and MPP3 toward pre-GMs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Gene set enrichment analysis (GSEA) revealed upregulation of genes involved in myeloid cell development (<xref ref-type="bibr" rid="bib9">Brown et al., 2006</xref>), CEBP targets (<xref ref-type="bibr" rid="bib18">Gery et al., 2005</xref>), and genes upregulated upon C/EBPα overexpression (<xref ref-type="bibr" rid="bib31">Loke et al., 2018</xref>) in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs compared to controls (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). C/EBP family are master transcription factors for myeloid differentiation (<xref ref-type="bibr" rid="bib4">Avellino and Delwel, 2017</xref>; <xref ref-type="bibr" rid="bib44">Rosenbauer and Tenen, 2007</xref>). RT-PCR analysis demonstrated a significant upregulation of <italic>Cepba</italic> in HSPCs, but not in GMPs (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). C/EBPα drives myelopoiesis and antagonizes lymphoid differentiation (<xref ref-type="bibr" rid="bib16">Fukuchi et al., 2006</xref>; <xref ref-type="bibr" rid="bib44">Rosenbauer and Tenen, 2007</xref>; <xref ref-type="bibr" rid="bib62">Xie et al., 2004</xref>). Disruption of <italic>Cebpa</italic> blocks the transition from CMPs to GMPs (<xref ref-type="bibr" rid="bib64">Zhang et al., 1997</xref>). So, we evaluated the contribution of de-repressed <italic>Cebpa</italic> in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs. First, we overexpressed <italic>Cebpa</italic> in WT LSK cells and cultured them on TSt-4 stromal cells. Only twofold upregulation of <italic>Cebpa</italic> was sufficient to enhance myeloid differentiation and suppress B cell differentiation of HSPCs (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Conversely, we next tested whether myeloid skewing of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs could be canceled by reducing <italic>Cebpa</italic> expression. We seeded HSPCs from <italic>Rosa26<sup>CreERT</sup></italic>, <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic>, and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup>Cebpa<sup>fl/+</sup></italic> mice on TSt-4 stromal cells and recombined <italic>Pcgf1<sup>fl</sup></italic> and <italic>Cebpa<sup>fl</sup></italic> alleles by supplementation of 4-hydroxytamoxifen (4-OHT) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Of note, the reduction in the levels of <italic>Cebpa</italic> expression by introducing a <italic>Cebpa<sup>fl/+</sup></italic> allele in <italic>Pcgf1<sup>Δ/Δ</sup></italic> LSK cells was sufficient to restore balanced production of myeloid and B cells by <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). These results demonstrate that de-repression of <italic>Cebpa</italic> largely accounts for at least the myeloid-biased differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Pcgf1</italic>-deficient hematopoietic stem and progenitor cells (HSPCs) undergo myeloid reprogramming.</title><p>(<bold>A</bold>) Principal component analyses (PCA) based on total gene expression obtained by RNA-seq of hematopoietic stem cells (HSCs), multipotent progenitors (MPPs), pre-GM, and granulocyte-macrophage progenitors (GMPs) from control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice. Magnified view of the boxed part is depicted on the right. (<bold>B</bold>) Gene set enrichment analysis (GSEA) using RNA-seq data. Summary of GSEA data of representative gene sets is shown. Normalized enrichment scores (NES), nominal p-values (NOM), and false discovery rates (FDR) are indicated. The gene sets used are indicated in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. (<bold>C</bold>) Quantitative RT-PCR analysis of <italic>Cebpa</italic> in LSK cells and GMPs. <italic>Hprt1</italic> was used to normalize the amount of input RNA. Data are shown as the mean ± SEM (n = 3). ***p&lt;0.001 by the Student’s <italic>t</italic>-test. (<bold>D</bold>) Effects of <italic>Cebpa</italic> overexpression on HSPC differentiation in vitro. LSK cells were transduced with either control (<italic>GFP</italic>) or <italic>Cebpa</italic> retrovirus, then cultured on TSt-4 stromal cells in the presence of IL-7 (upper). The proportions of myeloid (Mac1<sup>+</sup> and /or Gr-1<sup>+</sup>), B cells (CD19<sup>+</sup>), and others (Mac1<sup>-</sup>Gr-1<sup>-</sup>CD19<sup>-</sup>) among CD45.2<sup>+</sup>GFP<sup>+</sup> hematopoietic cells on day 17 of culture are indicated (lower left; n = 4 each). RT-qPCR analysis of <italic>Cebpa</italic> in LSK cells transduced with control or <italic>Cebpa</italic> retrovirus on day 14 of culture (n = 3). <italic>Hprt1</italic> was used to normalize the amount of input RNA (lower right). Each symbol is derived from an individual culture. Data are shown as the mean ± SEM. **p&lt;0.01, ***p&lt;0.001 by the Student’s <italic>t</italic>-test. (<bold>E</bold>) Impact of <italic>Cebpa</italic> haploinsufficiency on myeloid-biased differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs. LSK cells from <italic>Rosa26<sup>CreERT</sup></italic>, <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup>;Cebpa<sup>fl/+</sup></italic> mice were treated with 4-OHT (200 nM) for 2 d in culture to delete <italic>Pcgf1</italic> and <italic>Cebpa</italic>. Cells were further cultured on TSt-4 stromal cells in the presence of IL-7 (upper). The proportions of myeloid (Mac1<sup>+</sup> and /or Gr-1<sup>+</sup>), B cells (CD19<sup>+</sup>), and others (Mac1<sup>-</sup>Gr-1<sup>-</sup>CD19<sup>-</sup>) among CD45.2<sup>+</sup>GFP<sup>+</sup> hematopoietic cells on day 17 of culture are indicated (lower; n = 4 each；* versus control). Each symbol is derived from an individual culture (lower left). RT-qPCR data of <italic>Cebpa</italic> in LSK cells on day 14 of culture (n = 3). <italic>Hprt1</italic> was used to normalize the amount of input RNA (lower right). Data are shown as the mean ± SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by the Student’s <italic>t</italic>-test (lower left) or the one-way ANOVA (lower right).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Derepressed <italic>Cebpa</italic> accounts for the myeloid-biased differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic stem and progenitor cells (HSPCs).</title><p>(<bold>A</bold>) Deletion efficiency of <italic>Pcgf1</italic> and <italic>Cebpa</italic> in TSt-4 stromal co-culture in <xref ref-type="fig" rid="fig2">Figure 2E</xref> was assessed by genomic PCR in D45.2<sup>+</sup> hematopoietic cells treated and non-treated with 4-OHT. Floxed, floxed allele; Δ, floxed allele after the removal of targeted exons by Cre recombinase (lower). (<bold>B</bold>) Rescue experiments of the myeloid-biased repopulation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs. LSK cells from <italic>Rosa26<sup>CreERT</sup></italic> (control) and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> mice were transduced with control (GFP), <italic>Pcgf1</italic>, or <italic>Bmi1</italic> retrovirus, then transplanted into lethally irradiated CD45.1 recipient mice. <italic>Pcgf1</italic> was deleted by intraperitoneal injection of tamoxifen at 4 wk post-transplantation (upper). The proportions of myeloid (Mac-1<sup>+</sup> and/or Gr-1<sup>+</sup>), B cells (B220<sup>+</sup>), and T cells (CD4<sup>+</sup> or CD8<sup>+</sup>) among CD45.2<sup>+</sup>GFP<sup>+</sup> control (n = 4–5) and <italic>Pcgf1<sup>Δ/Δ</sup></italic> (n = 5) donor-derived hematopoietic cells in peripheral blood (PB) at 3 mo after transplantation are indicated (* versus GFP control) (middle). RT-qPCR analysis of <italic>Bmi1</italic> and <italic>Pcgf1</italic> in GFP<sup>+</sup> LSK cells purified from bone marrow (BM) of recipient mice receiving control or <italic>Pcgf1Δ/Δ</italic> LSK cells transduced with control, <italic>Bmi1</italic> or <italic>Pcgf1</italic> retrovirus (n = 3). <italic>Hprt1</italic> was used to normalize the amount of input RNA (lower; n=3). Data are shown as the mean ± SEM. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001 by the Student’s <italic>t</italic>-test. (<bold>C</bold>) Snapshots of RNA-seq signals at the <italic>Cebpe</italic> gene loci.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Uncropped gel images of <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig2-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig2-figsupp1-v2.tif"/></fig></fig-group><p>We next attempted to rescue the myeloid-biased differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs by exogenous <italic>Pcgf1</italic> or a canonical PRC1 gene <italic>Bmi1/Pcgf4</italic>. We transduced <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> HSPCs to induce <italic>Pcgf1</italic> or <italic>Bmi1</italic> expression, transplanted them into lethally irradiated mice, and deleted endogenous <italic>Pcgf1</italic> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). The myeloid skew in <italic>Pcgf1<sup>Δ/Δ</sup></italic> PB leukocytes was completely prevented by ectopic expression of <italic>Pcgf1</italic> but not of <italic>Bmi1</italic> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), highlighting distinct roles of non-canonical PRC1.1 and canonical PRC1 in hematopoietic differentiation.</p><p>We also noticed that the E2F targets (<xref ref-type="bibr" rid="bib22">Ishida et al., 2001</xref>) were downregulated in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), which may underlie the disturbed cell cycle progression and delayed proliferation observed in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). C/EBPα represses E2F-mediated transcription (<xref ref-type="bibr" rid="bib13">D’Alo’ et al., 2003</xref>; <xref ref-type="bibr" rid="bib53">Slomiany et al., 2000</xref>), inhibits HSC cell cycle entry (<xref ref-type="bibr" rid="bib63">Ye et al., 2013</xref>; <xref ref-type="bibr" rid="bib65">Zhang et al., 2004</xref>), and promotes precocious IL-1β-driven emergency myelopoiesis (<xref ref-type="bibr" rid="bib21">Higa et al., 2021</xref>). Thus, upregulated <italic>Cebpa</italic> upon PCGF1 loss may inhibit cell cycle and promote myeloid commitment of HSPCs.</p></sec><sec id="s2-3"><title>Deletion of <italic>Pcgf1</italic> affects levels of H2AK119ub1</title><p>To understand how PCGF1 loss affects H2AK119ub1 status in HSPCs, we performed chromatin immunoprecipitation followed by sequencing (ChIP-seq) analysis using control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs. Since none of the anti-PCGF1 antibodies were suitable for ChIP analysis, we used 3×Flag-PCGF1-expressing BM LK cells obtained by retrovirally transducing LSK cells and transplanting them to lethally irradiated mice. We defined ‘PRC1 targets’ and ‘PRC2 targets’ as genes with H2AK119ub1 and H3K27me3 enrichment greater than twofold over the input signals in control LSK cells at promoter regions (transcription start site [TSS] ± 2.0 kb), respectively (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). GSEA revealed that both PRC1 and PRC2 targets were upregulated in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs and GMPs (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). K-means clustering divided PRC1 targets into two clusters depending on the levels of H2AK119ub1 and H3K27me3. Cluster 1 genes (1835 RefSeq ID genes) were marked with high levels of H2AK119ub1 and H3K27me3 at promoter regions, while cluster 2 genes (2691 RefSeq ID genes) showed moderate levels of H2AK119ub1 and H3K27me3 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). PCGF1 showed stronger binding to the promoters of cluster 2 genes than cluster 1 genes (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Interestingly, only cluster 2 genes showed moderate but significant reductions in H2AK119ub1 and H3K27me3 levels in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The loss of PCGF1 was also significantly associated with de-repression of PRC1 target genes in clusters 1 and 2 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). These results suggest that cluster 2 genes are the major targets of PCGF1-containing PRC1.1 and <italic>Cebpa</italic> was included in cluster 2 genes. Bivalent genes, which are enriched for developmental regulator genes marked with both active and repressive histone marks (H3K4me3 and H3K27me3, respectively, mostly with H2AK119ub1), are classical targets of canonical PRC1 and PRC2 (<xref ref-type="bibr" rid="bib6">Bernstein et al., 2006</xref>; <xref ref-type="bibr" rid="bib28">Ku et al., 2008</xref>) and are implicated in multipotency of HSPCs (<xref ref-type="bibr" rid="bib38">Oguro et al., 2010</xref>). Of note, bivalent genes defined by our previous ChIP-seq data of HSPCs (<xref ref-type="bibr" rid="bib3">Aoyama et al., 2018</xref>; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were more enriched in cluster 1 genes than cluster 2 genes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>PCGF1 regulates local H2AK119ub1 levels in hematopoietic stem and progenitor cells (HSPCs).</title><p>(<bold>A</bold>) K-means clustering of 3×FLAG-PCGF1, H2AK119ub1, and H3K27me3 ChIP peaks around transcription start site (TSS) (±8.0 kb) of PRC1 target genes. The average levels of chromatin immunoprecipitation (ChIP) peaks in each cluster are plotted in upper columns. (<bold>B</bold>) Box-and-whisker plots showing H2AK119ub1, H3K27me3, and transcription levels of genes in PRC1 targets (clusters 1 and 2) and non-PRC1 targets in control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> LSK cells. Boxes represent 25–75 percentile ranges. The whiskers represent 10–90 percentile ranges. Horizontal bars represent medians. Mean values are indicated by ‘+’. **p&lt;0.01; ***p&lt;0.001 by the Student’s <italic>t</italic>-test. (<bold>C</bold>) Proportion of bivalent genes in PRC1 targets (clusters 1 and 2) and non-PRC1 targets in LSK cells. Bivalent genes were defined using our previous ChIP-seq data of wild-type LSK cells (<xref ref-type="bibr" rid="bib3">Aoyama et al., 2018</xref>). (<bold>D</bold>) Scatter plots showing the correlation of the fold enrichment values against the input signals (ChIP/Input) (TSS ± 2 kb) of H2AK119ub1 between control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> LSK cells. PRC1 targets are indicated in a green box. (<bold>E</bold>) Snapshots of Flag-PCGF1 and H2AK119ub1 ChIP signals at the <italic>Cebpa</italic> and <italic>Cebpe</italic> gene loci. (<bold>F</bold>) ChIP qPCR assays for H2AK119ub1 at the <italic>Cebpa</italic> promoter in control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> LSK cells. The relative amounts of immunoprecipitated DNA are depicted as a percentage of input DNA. Data are shown as the mean ± SEM (n = 3). ***p&lt;0.001 by the Student’s <italic>t</italic>-test. (<bold>G</bold>) Box-and-whisker plots showing ATAC signal levels at proximal promoters (TSS ± 2 kb) in <italic>Pcgf1<sup>Δ/Δ</sup></italic> CD135<sup>-</sup>LSK cells relative to those in control cells. The data of all ATAC peaks (n = 18,417), PCGF1 target genes (TG) (n = 670), and non-PCGF1 TG (n = 17,747) are shown. Boxes represent 25–75 percentile ranges. The whiskers represent 10–90 percentile ranges. Horizontal bars represent medians. Mean values are indicated by red crosses. ***p&lt;0.001 by the one-way ANOVA. (<bold>H</bold>) Top DNA motifs identified in ATAC peaks at proximal promoters (TSS ± 2 kb) positively or negatively enriched in <italic>Pcgf1<sup>Δ/Δ</sup></italic> CD135<sup>-</sup>LSK cells compared to corresponding controls.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig3-v2.tif"/></fig><p>We then defined ‘PCGF1 targets’ whose H2AK119ub1 levels were decreased by <italic>Pcgf1</italic> deletion greater than twofold at promoter regions in HSPCs (997 RefSeq ID genes; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). We found that <italic>Cebpa and Cebpe</italic> were included in PCGF1 targets, showed reductions in H2AK119ub1 levels (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>), and were de-repressed in expression in <italic>Pcgf1<sup>Δ/Δ</sup></italic> LSK cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). ChIP-qPCR confirmed a significant reduction in H2AK119ub1 levels at the promoter region of <italic>Cebpa</italic> in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). These results indicate that the deletion of <italic>Pcgf1</italic> compromises PRC1.1 function and causes precocious activation of key myeloid regulator genes in HSPCs.</p><p>To clarify whether the <italic>Pcgf1</italic> deletion has any impact on the chromatin accessibility in HSPCs, we performed an assay for transposase accessible chromatin with high-throughput sequencing (ATAC-seq) analysis using CD135<sup>–</sup>LSK HSPCs, which include HSCs and MPP1-3 but not lymphoid-primed MPP4. ATAC-seq profiles open chromatin regions enriched for transcriptional regulatory regions, such as promoters and enhancers. ATAC peaks were significantly enriched at the promoter regions of PCGF1 target genes, but not of PCGF1 non-target genes, in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs compared to the corresponding controls (<xref ref-type="fig" rid="fig3">Figure 3G</xref>), further validating de-repression of PCGF1 targets upon the deletion of <italic>Pcgf1</italic>. Motif analysis of ATAC peaks in the proximal promoter regions (TSS ± 2 kb) revealed that the CTCF motif, which has been reported to be associated with differentiation of HSCs (<xref ref-type="bibr" rid="bib10">Buenrostro et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Takayama et al., 2021</xref>), was highly enriched in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Interestingly, the other top-ranked motifs were related to stress response transcription factors, such as Bach family (Bach1 and 2), CNC family (Nrf2 and NF-E2), AP1 family, and Atf3 (<xref ref-type="fig" rid="fig3">Figure 3H</xref> and <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). In contrast, the binding motifs for transcription factors essential for T and B cell commitment, including HEB and E2A (<xref ref-type="bibr" rid="bib14">de Pooter and Kee, 2010</xref>), were negatively enriched in <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Together with the significant upregulation of <italic>Cebpa</italic> and <italic>Cebpe</italic> in <italic>Pcgf1<sup>Δ/Δ</sup></italic>HSPCs (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>), these results further support the notion that PRC1.1 deficiency caused precocious activation of myeloid differentiation program at the expense of lymphoid differentiation program in HSPCs.</p></sec><sec id="s2-4"><title>PCGF1 inhibition facilitates emergency myelopoiesis</title><p>Myeloid-biased hematopoiesis in <italic>Pcgf1</italic>-deficient mice reminded us of the myeloproliferative reactions caused by emergencies such as regeneration (<xref ref-type="bibr" rid="bib32">Manz and Boettcher, 2014</xref>). Individual GMPs scatter throughout the BM in the steady state, while expanding GMPs evolve into GMP clusters during regeneration, which, in turn, differentiate into granulocytes. Inducible activation of β-catenin and <italic>Irf8</italic> controls the formation and differentiation of GMP clusters, respectively (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). Immunofluorescence analyses of BM sections readily detected GMP clusters in steady-state <italic>Pcgf1<sup>Δ/Δ</sup></italic> BM (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), which was reminiscent of those observed during regeneration after 5-fluorouracil (5-FU) treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). To address whether PCGF1 also regulates myelopoiesis at the GMP level during regeneration, we challenged control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice with a single dose of 5-FU (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Consistent with the previous report (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>), control mice showed transient expansion of BM HSPCs and GMPs around day 14 and subsequent burst of circulating PB myeloid cells around day 21. In sharp contrast, <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice displayed sustained GMP expansion until day 28 without efficient production of PB myeloid cells, leading to the accumulation of excess GMPs (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>PCGF1 negatively regulates granulocyte-macrophage progenitor (GMP) self-renewal.</title><p>(<bold>A</bold>) Immunofluorescence staining of bone marrow (BM) sections from control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice. Magnified images are depicted in the middle panels. Dotted lines denote clusters of GMP (Lin<sup>–</sup>Sca-1<sup>–</sup>CD41<sup>–</sup>IL-7Rα<sup>–</sup>c-Kit<sup>+</sup>FcγR<sup>+</sup>) (c-Kit, red; FcγR, blue; merged, purple). The right panel shows c-Kit<sup>+</sup>FcγR<sup>+</sup> purple cell area in BM sections relative to that in control. Data are shown as the mean ± SEM (n = 3). (<bold>B</bold>) Strategy to analyze emergency myelopoiesis induced by one shot of 5-FU (150 mg/kg). (<bold>C</bold>) Absolute numbers of total BM cells, LSK cells, GMPs, and Mac-1<sup>+</sup> myeloid cells in a unilateral pair of femur and tibia and Mac-1<sup>+</sup> myeloid cells in peripheral blood (PB) at the indicated time points post-5-FU injection. Data are shown as the mean ± SEM (n = 4；* versus day 0 for each genotype). Circles represent the data from individual mice. (<bold>D</bold>) A Venn diagram showing the overlap between upregulated differentially expressed genes (DEGs) in 5-FU treated GMPs on day 8 and upregulated DEGs in <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs. (<bold>E</bold>) Quantitative RT-PCR analysis of <italic>Hoxa9</italic> in LSK cells and GMPs. <italic>Hprt1</italic> was used to normalize the amount of input RNA. Data are shown as the mean ± SEM (n = 3). (<bold>F</bold>) Chromatin immunoprecipitation (ChIP) qPCR assays for H2AK119ub1 at the <italic>Hoxa9</italic> locus in GMPs from WT mice on days 0, 10, and 14 post-5-FU treatment. The relative amounts of immunoprecipitated DNA are depicted as a percentage of input DNA. Data are shown as the mean ± SEM (n = 3). (<bold>G</bold>) Fold changes in H2AK119ub1 levels in <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs relative to control GMPs at the promoters of non-DEGs and DEGs up- and downregulated in day 8 GMPs compared to day 0 GMPs post-5-FU treatment. (<bold>H</bold>) UMAP plots illustrating the identification of cell clusters based on single-cell transcriptomic profiling of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> myeloid progenitors (Lin<sup>–</sup>Sca-1<sup>–</sup>c-Kit<sup>+</sup>). (<bold>I</bold>) Principal component analysis (PCA) plots of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs individually and in combination. (<bold>J</bold>) UMAP and violin plots showing expression of <italic>Hoxa9, Irf8, Csf1r</italic>, and <italic>Il-6ra</italic> in control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> myeloid progenitors. (<bold>K</bold>) Gene Ontology and pathway enrichment analyses using DEGs in the indicated clusters. (<bold>L</bold>) Proportion of common myeloid progenitors (CMPs), megakaryocyte-erythroid progenitors (MEPs), steady-state GMPs (ssGMPs), and self-renewing GMPs (srGMPs) in control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> myeloid progenitors. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001 by the Student’s <italic>t</italic>-test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Granulocyte-macrophage progenitor (GMP) expansion during regeneration.</title><p>(<bold>A</bold>) Representative immunofluorescence staining of bone marrow (BM) sections from 5-FU-treated wild-type mice. Dotted lines denote clusters of GMPs (Lin<sup>–</sup>Sca-1<sup>–</sup>CD41<sup>–</sup>IL-7Rα<sup>–</sup>c-Kit<sup>+</sup>) (red). (<bold>B</bold>) MA plot showing the relationship between average expression (count per million in Log: logCPM) and fold change (logFC) in GMPs from 5-FU-treated WT mice on days 0 and 8. The red and blue dots represent upregulated (1862 genes) and downregulated (1938 genes) differentially expressed genes (DEGs) (5-FU day 8 vs. day 0). (<bold>C</bold>) K-means clustering of DEGs defined in (<bold>B</bold>). Heatmap shows the z-scores of expression values. (<bold>D</bold>) Snapshots of RNA-Seq and Flag-PCGF1 and H2AK119ub chromatin immunoprecipitation (ChIP) signals at the <italic>Hoxa7</italic> and <italic>Hoxa9</italic> gene loci. (<bold>E</bold>) <italic>Pcgf1</italic> expression in GMPs during regeneration in 5-FU-treated WT mice. FPKM values of RNA-seq data (n = 2) are indicated.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig4-figsupp1-v2.tif"/></fig></fig-group><p>GMPs can be divided into steady-state GMPs (ssGMP) and self-renewing GMPs (srGMP), the latter of which transiently increase during regeneration (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). We performed RNA-seq analysis of GMPs isolated from 5-FU-treated WT mice at various time points (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>), and defined differentially expressed genes (DEGs) on day 8 after 5-FU treatment since srGMPs reportedly most expand on that day (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>; <xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). Of note, a significant portion of upregulated DEGs in day 8 5-FU-treated GMPs were also upregulated in <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs (<xref ref-type="fig" rid="fig4">Figure 4D</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). These overlapping genes included <italic>Hoxa9</italic>, a PRC1.1 target (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>; <xref ref-type="bibr" rid="bib45">Ross et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Shinoda et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>), which is highly expressed in srGMPs (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). RT-qPCR confirmed significantly higher expression of <italic>Hoxa9</italic> in <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs than control GMPs (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Correspondingly, 5-FU treatment transiently decreased H2AK119ub1 levels at <italic>Hoxa9</italic> locus around day 10 (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). ChIP-seq analysis also revealed significant reductions in H2AK119ub1 levels at promoters of upregulated DEGs in day 8 5-FU-treated GMPs in <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). These results suggest that transient inhibition of PRC1.1 de-represses genes critical to expand srGMP during myeloid regeneration, although the expression of PRC1.1 genes remained largely unchanged during regeneration (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>).</p><p>To better understand the role of PRC1.1 in myeloid progenitors, we performed single-cell RNA-seq (scRNA-seq) of Lin<sup>–</sup>Sca-1<sup>–</sup>c-Kit<sup>+</sup> myeloid progenitors from control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice at steady state. We used data from 6171 control and 6198 <italic>Pcgf1<sup>Δ/Δ</sup></italic> single cells and identified 10 major clusters based on dimension reduction by UMAP (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Functional annotation of respective UMAP clusters using previously reported myeloid progenitor cell gene expression profiles (<xref ref-type="bibr" rid="bib36">Nestorowa et al., 2016</xref>) assigned clusters 0, 2, and 4 to GMPs (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). PCA subdivided GMPs into two major groups (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). These two groups exhibited distinct expression profiles of <italic>Hoxa9</italic>, <italic>Irf8</italic>, <italic>Csf1r</italic>, and <italic>Il6ra</italic>, key genes differentially expressed between ssGMPs (<italic>Hoxa9</italic><sup>lo</sup>, <italic>Irf8</italic><sup>hi</sup>, <italic>Csf1r</italic><sup>hi</sup>, <italic>Il6ra</italic><sup>hi</sup>) and srGMPs (<italic>Hoxa9</italic><sup>hi</sup>, <italic>Irf8</italic><sup>lo</sup>, <italic>Csf1r</italic><sup>lo</sup>, <italic>Il6ra</italic><sup>lo</sup>) (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>), and we classified clusters 2 and 4 as ssGMPs and cluster 0 as srGMPs (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). Gene Ontology and pathway enrichment analyses using DEGs (cluster 2 or 4 versus cluster 0) revealed that clusters 2 and 4 represented more mature myeloid cell populations than cluster 0 (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). As expected, <italic>Pcgf1<sup>Δ/Δ</sup></italic> myeloid progenitors had a greater proportion of total GMPs including srGMPs than controls (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). Of note, the frequency of srGMPs was also increased in <italic>Pcgf1<sup>Δ/Δ</sup></italic> myeloid progenitors (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). These results indicate that PRC1.1 restricts expansion of self-renewing GMPs and suggest that transient PRC1.1 inhibition allows for temporal amplification of GMPs and their subsequent differentiation to mature myeloid cells.</p></sec><sec id="s2-5"><title>PCGF1 restricts GMP self-renewal network</title><p>To further investigate the mechanism by which PCGF1 regulates GMPs, we took advantage of in vitro culture experiments. Remarkably, <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs displayed better proliferation than control GMPs under myeloid-expanding culture conditions (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Moreover, while comparable numbers of cells expressing immunophenotypic GMP markers (CD34<sup>+</sup>FcγR<sup>+</sup>c-Kit<sup>+</sup>Sca-1<sup>-</sup>Lineage<sup>-</sup>) (immunophenotypic GMPs) were produced by control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSCs on day 7 of culture, control HSCs showed a rapid decline in immunophenotypic GMP production afterward but <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSCs persistently produced immunophenotypic GMPs until day 23 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Of interest, differentiation of the expanded <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs was largely blocked, as indicated by reduced Mac1<sup>+</sup> differentiated myeloid cells/GMP ratios until day 19 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), suggesting that <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs underwent enhanced self-renewal rather than differentiation. However, <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs did not lose its differentiation potential to mature myeloid cells and did not show evident differentiation block, with more Mac1<sup>+</sup> cells ultimately generated from HSC cultures than control GMPs (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). This was also consistent that the number of mature myeloid cells expressing myeloid differentiation markers increased in <italic>Pcgf1<sup>Δ/Δ</sup></italic> BM and spleen (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C and D</xref>). Furthermore, <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs showed remarkably sustained colony formation activity upon serial replating with myeloid cytokines, which is in line with the elevated self-renewing activity of <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>PCGF1 restricts self-renewal of granulocyte-macrophage progenitors (GMPs) by attenuating <italic>Hoxa9</italic> expression.</title><p>(<bold>A</bold>) Growth of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs in culture. Cells were cultured in triplicate under myeloid culture condition-2 (25 ng/mL SCF, TPO, Flt3L, and IL-11 and 10 ng/mL IL-3 and GM-CSF). Data are shown as the mean ± SD (n = 3). (<bold>B</bold>) Growth of control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic stem cells (HSCs) under myeloid culture condition-2 (25 ng/mL SCF, TPO, Flt3L, and IL-11 and 10 ng/mL IL-3 and GM-CSF). Cells were cultured in triplicate. The proportion of GMPs in culture is depicted on the right panel. Data are shown as the mean ± SD (n = 3). (<bold>C</bold>) Replating assay data. 700 LSK cells were plated in a methylcellulose medium containing 20 ng/mL of SCF, TPO, IL-3, and GM-CSF. After 10 d of culture, colonies were counted and pooled, and 1 × 10<sup>4</sup> cells were then replated in the same medium every 7 d. Data are shown as the mean ± SEM (n = 3). (<bold>D</bold>) Proportion of immunophenotypic GMPs with nuclear β-catenin in control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> immunophenotypic GMPs in HSC culture on day 16 in (<bold>B</bold>). Representative immunofluorescent signals of β-catenin in control immunophenotypic GMPs are shown on the right panel. Data are shown as the mean ± SEM (n = 3). (<bold>E</bold>) Quantitative RT-PCR analysis of <italic>Hoxa9, Irf8, Csf1r</italic>, and <italic>Il-6ra</italic> in sorted control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> immunophenotypic GMPs in HSC culture in (<bold>B</bold>) at the indicated time points. <italic>Hprt1</italic> was used to normalize the amount of input RNA. Data are shown as the mean ± SEM (n = 3). (<bold>F</bold>) Gene set enrichment analysis (GSEA) using RNA-seq data. The gene sets used are indicated in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. (<bold>G</bold>) Growth of mock control and <italic>Hoxa9</italic>-expressing LSK cells. LSK cells transduced with a <italic>Hoxa9</italic> retrovirus harboring mCherry marker gene were cultured in triplicate under myeloid culture condition-2 (25 ng/mL SCF, TPO, Flt3L, and IL-11 and 10 ng/mL IL-3 and GM-CSF). The proportion of GMPs in culture is depicted on the right panel. Data are shown as the mean ± SD (n = 4). (<bold>H</bold>) Proportion of GMPs with nuclear β-catenin in mock control and <italic>Hoxa9</italic>-expressing GMPs in LSK culture on day 12 in (<bold>G</bold>). Data are shown as the mean ± SEM (n = 5–6). (<bold>I</bold>) Model of the molecular network controlling GMP self-renewal and differentiation. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001 by the Student’s <italic>t</italic>-test (<bold>A–D</bold>, <bold>H</bold>, and <bold>G</bold>) or the one-way ANOVA (<bold>E</bold>). Each symbol is derived from an individual culture.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Granulocyte-macrophage progenitor (GMP) expansion in the absence of PCGF1.</title><p>(<bold>A</bold>) Cell number of Mac1<sup>+</sup> differentiated myeloid cells in control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic stem cell (HSC) cultures in <xref ref-type="fig" rid="fig5">Figure 5B</xref> (upper). The ratio of the number of Mac1<sup>+</sup> differentiated myeloid cells and GMPs. The significance relative to day 5 is shown (lower). Data are shown as the mean ± SEM (n = 3). **p&lt;0.01; ***p&lt;0.001 by the Student’s <italic>t</italic>-test (upper) or the one-way ANOVA (lower). (<bold>B</bold>) RT-qPCR analysis of <italic>Hoxa9</italic> in primary and mCherry-positive GMPs purified from Mock and <italic>Hoxa9</italic> cultures at day 2 in <xref ref-type="fig" rid="fig5">Figure 5G</xref>. Data are shown as the mean ± SEM (n = 3). <italic>Hprt1</italic> was used to normalize the amount of input RNA. ***p&lt;0.001 by the one-way ANOVA. (<bold>C</bold>) RT-qPCR analysis of <italic>Ctnnb1</italic> in mCherry-positive GMPs purified from Mock and <italic>Hoxa9</italic> cultures at day 12 in <xref ref-type="fig" rid="fig5">Figure 5G</xref>. Data are shown as the mean ± SEM (n = 3). **p&lt;0.01 by the Student’s <italic>t</italic>-test.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig5-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig5-figsupp1-v2.tif"/></fig></fig-group><p>srGMPs have increased levels of nuclear β-catenin, which is known to confer aberrant self-renewal features to leukemic GMPs (<xref ref-type="bibr" rid="bib61">Wang et al., 2010</xref>) and directly suppresses <italic>Irf8</italic> expression (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). The proportion of nuclear β-catenin was significantly increased in <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs at later time points of culture when GMPs in control culture shrunk but GMPs in <italic>Pcgf1<sup>Δ/Δ</sup></italic> culture kept expanding (<xref ref-type="fig" rid="fig5">Figure 5B and D</xref>). <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs in culture possessed a transcriptional profile typical to srGMPs; upregulation of <italic>Hoxa9</italic> and downregulation of <italic>Irf8</italic>, <italic>Csf1r</italic>, and <italic>Il6ra</italic> (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). GSEA revealed activation of the Wnt/β-catenin pathway (<xref ref-type="bibr" rid="bib51">Shooshtarizadeh et al., 2019</xref>) and downregulation of the Irf8 targets (<xref ref-type="bibr" rid="bib29">Kubosaki et al., 2010</xref>) in <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). We hypothesized that <italic>Hoxa9</italic>, a direct target of PCGF1, could have a role in the GMP self-renewal network. Overexpression of <italic>Hoxa9</italic> in HSPCs significantly enhanced their growth and induced persistent production of GMPs for a long period (<xref ref-type="fig" rid="fig5">Figure 5G</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Most <italic>Hoxa9</italic>-overexpressing GMPs had nuclear β-catenin (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). These results indicate that HoxaA9 can reinforce activation of β-catenin, thus placing Hoxa9 as a component of the GMP self-renewal network and PCGF1-PRC1.1 as a negative regulator of this network (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). The promoter region of the <italic>Ctnnb1</italic> gene contains at least one predicted sequence for Hoxa9 binding (<named-content content-type="sequence">CTTATAAATCG</named-content>) (data not shown). We performed qPCR analysis using <italic>Hoxa9</italic> overexpression samples at day 12 of culture, in which nuclear localization of β-catenin was observed (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). <italic>Ctnnb1</italic> gene expression was slightly but significantly upregulated in <italic>Hoxa9</italic> overexpression samples compared to mock control (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). These results raise the possibility that Hoxa9 is a direct transcriptional activator of the <italic>Ctnnb1</italic> gene, but this warrants further analysis.</p></sec><sec id="s2-6"><title>Constitutive PCGF1 loss promotes malignant transformation</title><p>In leukemia, GMP clusters are constantly produced owing to persistent activation of the myeloid self-renewal network and a lack of termination cytokines that normally restore HSC quiescence (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). A significant portion of <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice, which exhibit constant production of GMP clusters, developed lethal myeloproliferative neoplasms (MPN) with severe anemia and massive accumulation of mature myeloid cells in PB, BM, and spleen (<xref ref-type="fig" rid="fig6">Figure 6A–E</xref>). Morphological analysis of BM and spleen sections revealed accumulation of mature myeloid cells but no obvious differentiation block like acute myeloid leukemia (AML) was observed (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Indeed, AML was not observed in long-term observation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice. It is assumed that the epigenetic status that allows GMP self-renewal was enforced over time in the absence of <italic>Pcgf1</italic>, leading to enhanced production of mature myeloid cells that mimic MPN. A part of <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice also developed lethal T-cell acute lymphoblastic leukemia (T-ALL) (<xref ref-type="fig" rid="fig6">Figure 6A and G</xref>) like <italic>Bcor</italic> mutant mice (<xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>). These results indicate that constitutive activation of the GMP self-renewal network in <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice serves to promote malignant transformation. Taken together, these results highlight the importance of PRC1.1-dependent suppression of the myeloid self-renewing network to prevent malignant transformation.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Development of lethal myeloproliferative neoplasm in <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice.</title><p>(<bold>A</bold>) Kaplan–Meier survival curves of control (n = 7) and <italic>Pcgf1<sup>Δ/Δ</sup></italic> (n = 25) mice after the tamoxifen injection. (<bold>B</bold>) White blood cell (WBC) and hemoglobin (Hb) in peripheral blood (PB) from control (n = 8) and moribund <italic>Pcgf1<sup>Δ/Δ</sup></italic> myeloproliferative neoplasms (MPN) mice (n = 6). Bars indicate median values. (<bold>C</bold>) Absolute numbers of total bone marrow (BM) cells and spleen weight in control (n = 8) and moribund <italic>Pcgf1<sup>Δ/Δ</sup></italic> MPN mice (n = 6). (<bold>D</bold>) The proportions of Mac-1<sup>+</sup> and/or Gr-1<sup>+</sup> myeloid cells, B220<sup>+</sup> B cells, and CD4<sup>+</sup> or CD8<sup>+</sup> T cells in PB and BM in control (n = 8) and moribund <italic>Pcgf1<sup>Δ/Δ</sup></italic> MPN mice (n = 6). Data are shown as the mean ± SEM. (<bold>E</bold>) Representative flow cytometric profiles of PB, BM, and spleen of control and moribund <italic>Pcgf1<sup>Δ/Δ</sup></italic> MPN mice. The percentages of gated populations over CD45.2<sup>+</sup> live cells are indicated. (<bold>F</bold>) Representative histology of BM and spleen from control and moribund <italic>Pcgf1<sup>Δ/Δ</sup></italic> MPN mice observed by hematoxylin-eosin staining (left). The high-power field images of BM from control and moribund <italic>Pcgf1<sup>Δ/Δ</sup></italic> MPN mice observed by hematoxylin-eosin staining (right). (<bold>G</bold>) Representative flow cytometric profiles of thymus from control mice and moribund <italic>Pcgf1<sup>Δ/Δ</sup></italic> T-ALL mice. (<bold>H</bold>) Model for the stage-specific roles of non-canonical PRC1 in hematopoietic differentiation. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001 by the Student’s <italic>t</italic>-test. Each symbol is derived from an individual mouse.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw data for <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83004-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83004-fig6-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we demonstrated that PCGF1 contributes to balanced hematopoiesis by restricting precocious myeloid commitment of HSPCs and expansion of myeloid progenitors while its inhibition promotes emergency myelopoiesis and myeloid transformation. These findings present a sharp contrast with PCGF4/BMI1 essential for self-renewal of HSCs (<xref ref-type="bibr" rid="bib25">Iwama et al., 2004</xref>; <xref ref-type="bibr" rid="bib37">Oguro et al., 2006</xref>; <xref ref-type="bibr" rid="bib40">Park et al., 2003</xref>) and underscore distinct functions between canonical PRC1 and non-canonical PRC1.1 in hematopoiesis (<xref ref-type="fig" rid="fig6">Figure 6H</xref>).</p><p>PcG and trithorax group proteins mark developmental regulator gene promoters with bivalent histone domains to keep them poised for activation in ES cells (<xref ref-type="bibr" rid="bib6">Bernstein et al., 2006</xref>). We previously reported that canonical PRC1 reinforces bivalent domains at the B cell regulator genes, <italic>Ebf1</italic> and <italic>Pax5</italic>, to maintain B cell lineage commitment poised for activation in HSPCs (<xref ref-type="bibr" rid="bib38">Oguro et al., 2010</xref>). In contrast, PCGF1 appeared to target non-bivalent PRC1 target genes marked with moderate levels of H2AK119ub1 and H3K27me3. Among these, PCGF1 targets myeloid regulator genes, such as <italic>Cebpa</italic>, thereby negatively regulating myeloid commitment. Our findings indicate that canonical and non-canonical PRC1 restrict the lymphoid and myeloid commitment of HSPCs, respectively, by targeting different transcriptional programs of differentiation, thereby fine-tuning the balance of HSPC commitment (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Although there might be considerable functional redundancy between canonical and non-canonical PRC1 complexes, our results uncovered a unique function of PRC1.1 in the lineage commitment of HSPCs. The reduction in the levels of <italic>Cebpa</italic> expression by introducing a <italic>Cebpa<sup>fl/+</sup></italic> allele in <italic>Pcgf1<sup>Δ/Δ</sup></italic> LSK cells was sufficient to restore balanced production of myeloid and B cells by <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs in culture (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). However, we could not confirm these data in mice probably due to inefficient deletion of <italic>Cebpa</italic> using a Cre-ERT system (data not shown). The real impact of de-repressed <italic>Cebpa</italic> in myeloid-biased differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs requires further validation in vivo.</p><p>Myeloid-biased output from HSPCs is one of the hallmarks of emergency hematopoiesis (<xref ref-type="bibr" rid="bib58">Trumpp et al., 2010</xref>; <xref ref-type="bibr" rid="bib66">Zhao and Baltimore, 2015</xref>). In mouse models of regeneration, myeloid-biased MPP2 and MPP3 are transiently overproduced, suggesting that HSCs produce functionally distinct lineage-biased MPPs to adapt blood production to hematopoietic demands (<xref ref-type="bibr" rid="bib41">Pietras et al., 2015</xref>). In the present study, we found that <italic>Pcgf1</italic>-deficient hematopoiesis recapitulates sustained emergency myelopoiesis, although the production of circulating myeloid cells was not enhanced. Expanding GMPs, GMP clusters during regeneration, which, in turn, differentiate into granulocytes (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). Of note, PCGF1 loss induced constitutive GMP cluster formation at steady state and sustained GMP expansion in mice after myeloablation and in culture. Correspondingly, <italic>Pcgf1</italic>-deficient mice had a greater number of self-renewing GMPs than control mice. This unique phenotype may implicate the importance of transient but not constitutive PCGF1 repression for proper myeloid regeneration. β-catenin and <italic>Irf8</italic> constitute an inducible self-renewal progenitor network controlling GMP cluster formation, with β-catenin directly suppressing <italic>Irf8</italic> expression while restoration of <italic>Irf8</italic> expression terminating the self-renewal network and inducing GMP differentiation (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>; <xref ref-type="fig" rid="fig5">Figure 5I</xref>). <italic>Hoxa9</italic>, which is upregulated in srGMPs, is one of the PRC1.1 targets in myeloid progenitors (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>; <xref ref-type="bibr" rid="bib45">Ross et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Shinoda et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>). We demonstrated that <italic>Hoxa9</italic> expression activates β-catenin and promotes GMP self-renewal, identifying Hoxa9 as a component of the GMP self-renewal network. Of note, PRC1.1 is transiently inhibited to de-repress such GMP self-renewal network genes. This transient nature of PRC1.1 inhibition allows for srGMP expansion and GMP cluster formation followed by proper differentiation of expanded GMPs. As expression levels of PRC1.1 components remained unchanged during hematopoietic regeneration, non-canonical PRC1.1 activity could be modulated by post-translational modifications in response to extracellular stimuli like canonical PRC1 (<xref ref-type="bibr" rid="bib5">Banerjee Mustafi et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Nacerddine et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Voncken et al., 2005</xref>). How extrinsic signals modulate PRC1.1 functions to regulate myelopoiesis remains an important question.</p><p>The molecular machineries that drive emergency myelopoiesis are often hijacked by transformed cells (<xref ref-type="bibr" rid="bib20">Hérault et al., 2017</xref>). A significant portion of <italic>Pcgf1</italic>-deficient mice eventually developed lethal MPN after a sustained myeloproliferative state. These findings indicate that PRC1.1 functions as a critical negative regulator of myeloid transformation. Among the components of PRC1.1, <italic>BCOR</italic> and <italic>BCLRL1</italic>, but not <italic>PCGF1</italic> are targeted by somatic gene mutations in various hematological malignancies, including myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) (<xref ref-type="bibr" rid="bib23">Isshiki and Iwama, 2018</xref>). We reported that mice expressing a carboxyl-terminal truncated BCOR, which cannot interact with PCGF1, showed myeloid-biased hematopoiesis like <italic>Pcgf1</italic>-deficient mice. Importantly, HSPCs in these mice showed a growth advantage in the myeloid compartment, which was further enhanced by the concurrent deletion of <italic>Tet2</italic>, leading to the development of lethal MDS (<xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>). De-repression of myeloid regulator genes, such as <italic>Cebp</italic> family and <italic>Hoxa</italic> cluster genes, were also detected in <italic>Bcor</italic> mutant progenitor cells (<xref ref-type="bibr" rid="bib57">Tara et al., 2018</xref>). These findings also support the idea that PRC1.1 restricts myeloid transformation by transcriptionally repressing aberrant activation of myeloid regeneration programs.</p><p>Collectively, our findings highlight a critical role of PRC1.1 in coordinating steady-state and emergency hematopoiesis and preventing malignant transformation. They also suggest that transient inhibition of PRC1.1 would be a novel approach to temporarily induce emergency myelopoiesis and enhance myeloid cell supply while avoiding the potential risk for malignant transformation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>Wild-type mice (C57BL/6) and <italic>Rosa::Cre-ERT2</italic> mice were purchased from the Japan SLC and TaconicArtemis GmbH, respectively. <italic>Pcgf1<sup>fl</sup></italic> and <italic>Cebpa<sup>fl</sup></italic> mice were kindly provided by Haruhiko Koseki and Daniel G. Tenen, respectively, and previously reported (<xref ref-type="bibr" rid="bib1">Almeida et al., 2017</xref>; <xref ref-type="bibr" rid="bib65">Zhang et al., 2004</xref>). All experiments using mice were performed in accordance with our institutional guidelines for the use of laboratory animals and approved by the Review Board for Animal Experiments of Chiba University (approval ID: 30-56) and the University of Tokyo (approval ID: PA18-03).</p></sec><sec id="s4-2"><title>Bone marrow transplantation</title><p>To generate hematopoietic cell-specific <italic>Pcgf1</italic> KO mice, we transplanted total BM cells (5 × 10<sup>6</sup>) from <italic>Rosa26<sup>CreERT</sup></italic> and <italic>Rosa26<sup>CreERT</sup>;Pcgf1<sup>fl/fl</sup></italic> mice into lethally irradiated (9.5 Gy) CD45.1 recipient mice. For competitive bone marrow transplantation assay, we transplanted total BM cells (2 × 10<sup>6</sup>) from CD45.2 donor mice with CD45.1<sup>+</sup> competitor total BM cells (2 × 10<sup>6</sup>) into lethally irradiated (9.5 Gy) CD45.1 recipient mice. To induce Cre activity, transplanted mice were injected with 100 μL of tamoxifen (Sigma-Aldrich) dissolved in corn oil (Sigma-Aldrich) at a concentration of 10 mg/mL intraperitoneally once a day for five consecutive days 4 wk after transplantation.</p></sec><sec id="s4-3"><title>Locus-specific genotyping of <italic>Pcgf1, Cebpa,</italic> and <italic>Rosa::Cre-ERT</italic></title><p>To detect <italic>Pcgf1<sup>fl</sup></italic>, <italic>Pcgf1<sup>Δ</sup></italic>, <italic>Cebpa<sup>fl</sup></italic>, <italic>Cebpa<sup>Δ</sup></italic>, and <italic>Rosa::Cre-ERT</italic> PCR reactions were performed using the specific oligonucleotides. The oligonucleotide sequences used are shown in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p></sec><sec id="s4-4"><title>5-FU challenge</title><p>8–12-week-old wild-type mice or control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> were injected with 300 μL PBS or 150 mg/kg (3.75 mg per 25 g body weight mouse) 5-FU (Kyowa KIRIN) dissolved in 300 μL PBS intraperitoneally once.</p></sec><sec id="s4-5"><title>Flow cytometry analyses and antibodies</title><p>The monoclonal antibodies recognizing the following antigens were used in flow cytometry and cell sorting: CD45.1 (A20), CD45.2 (104), Gr-1 (RB6-8C5), CD11b/Mac-1 (M1/70), Ter-119 (TER-119), B220 (RA3-6B2), CD127/IL-7R (SB/119), CD4 (GK1.5), CD8a (53–6.7), CD117/c-Kit (2B8), Sca-1 (D7), CD34 (RAM34), CD150 (TC15-12F12.2), CD48 (HM48-1), CD135 (A2F10), CD16/32/FcγRII-III (93), CD41 (eBioMWReg30), CD105 (MJ7/18), Ly6D (49-H4), Ly6G (HK1.4), Ly6G (1A8), F4/80 (BM8), lineage mixture (Gr-1, Mac-1, Ter-119, CD127/IL-7R, B220, CD4, CD8α), and lineage mixture for CLP (Gr-1, Mac-1, Ter-119, B220, CD4, CD8α). Monoclonal antibodies were purchased from BioLegend, Tonbo Biosciences, Thermo Fisher Scientific, or BD Biosciences. Dead cells were eliminated by staining with 0.5 μg/mL propidium iodide (Sigma-Aldrich). All flow cytometric analyses and cell sorting were performed on FACSAria IIIu, FACSCanto II, and FACSCelesta (BD Biosciences). Cell surface protein expression used to define hematopoietic cell types were as follows:</p><list list-type="simple"><list-item><p>HSC: CD150<sup>+</sup>CD48<sup>-</sup>CD135<sup>-</sup>CD34<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>MPP1: CD150<sup>+</sup>CD48<sup>-</sup>CD135<sup>-</sup>CD34<sup>+</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>MPP2: CD150<sup>+</sup>CD48<sup>+</sup>CD135<sup>-</sup>CD34<sup>+</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>MPP3: CD150<sup>-</sup>CD48<sup>+</sup>CD135<sup>-</sup>CD34<sup>+</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>MPP4: CD150<sup>-</sup>CD48<sup>+</sup>CD135<sup>+</sup>CD34<sup>+</sup>c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>CMP: CD34<sup>+</sup>FcγR<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>-</sup>Lineage<sup>-</sup></p></list-item><list-item><p>GMP: CD34<sup>+</sup>FcγR<sup>+</sup>c-Kit<sup>+</sup>Sca-1<sup>-</sup>Lineage<sup>-</sup></p></list-item><list-item><p>MEP: CD34<sup>-</sup>FcγR<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>-</sup>Lineage<sup>-</sup></p></list-item><list-item><p>pre-GM: CD150<sup>-</sup>CD105<sup>-</sup>FcγR<sup>-</sup>CD41<sup>-</sup>c-Kit<sup>+</sup>Sca-1<sup>-</sup>Lineage<sup>-</sup></p></list-item><list-item><p>CLP: c-Kit<sup>low</sup>Sca-1<sup>low</sup>CD135<sup>+</sup>IL7R<sup>+</sup>Lineage (for CLP)<sup>-</sup></p></list-item><list-item><p>ALP: Ly6D<sup>-</sup>cKit<sup>low</sup>Sca-1<sup>low</sup>CD135<sup>+</sup>IL7R<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>BLP: Ly6D<sup>+</sup>cKit<sup>low</sup>Sca-1<sup>low</sup>CD135<sup>+</sup>IL7R<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>LSK: c-Kit<sup>+</sup>Sca-1<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>LK: c-Kit<sup>+</sup>Lineage<sup>-</sup></p></list-item><list-item><p>Pro-B: B220<sup>+</sup>CD43<sup>+</sup>IgM<sup>-</sup></p></list-item><list-item><p>Pre-B: B220<sup>+</sup>CD43<sup>-</sup>IgM<sup>-</sup></p></list-item></list></sec><sec id="s4-6"><title>Quantitative RT-PCR</title><p>Total RNA was extracted using a RNeasy Micro Plus Kit (QIAGEN) or TRIZOL LS solution (MOR) and reverse transcribed by the SuperScript IV First-Strand Synthesis System (Invitrogen) or the ReverTra Ace α- (TOYOBO) with an oligo-dT primer. Real-time quantitative PCR was performed with a StepOnePlus Real-Time PCR System (Life Technologies) using FastStart Universal Probe Master (Roche) and the indicated combinations of the Universal Probe Library (Roche), or TB Green Premix Ex Taq II (TaKaRa Bio). All data are presented as relative expression levels normalized to <italic>Hprt</italic> expression. The primer sequences used are shown in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> (<xref ref-type="bibr" rid="bib34">Murakami et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Sonntag et al., 2018</xref>).</p></sec><sec id="s4-7"><title>Limiting dilution assay</title><p>For in vivo limiting dilution assay, we transplanted limiting numbers of total BM cells (1 × 10<sup>4</sup>, 4 × 10<sup>4</sup>, 8 × 10<sup>4</sup>, and 2 × 10<sup>5</sup>) isolated from primary recipients (control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice 1 mo after tamoxifen injections) with CD45.1<sup>+</sup> competitor total BM cells (2 × 10<sup>5</sup>) into lethally irradiated CD45.1 recipient mice. PB analyses were performed at 16 wk after transplantation.</p><p>For in vitro limiting dilution assay, we sorted HSCs from control and <italic>Pcgf1<sup>Δ/Δ</sup></italic> mice 1 mo after tamoxifen injections and cultured limiting numbers of the cells (1, 5, 25, and 125) with TSt-4 (B cells) or TSt-4/DLL1 stromal cells (T cells) in RPMI (Thermo Fisher Scientific) supplemented with 10% BSA (093001; STEMCELL Technologies), 50 μM 2-ME (Sigma-Aldrich), 100 μM MEM Non-Essential Amino Acids solution (Gibco), 100 μM sodium pyruvate (Gibco), and 2 ng/mL recombinant mouse IL-7 (577802; BioLegend) for 28 d. The generation of CD19<sup>+</sup> B cells or Thy1.2<sup>+</sup> T cells in each well was detected by flow cytometry.</p></sec><sec id="s4-8"><title>Cell cycle assay</title><p>BM cells were stained with antibodies against cell-surface markers. After washing, cells were fixed and permeabilized with a BD Phosflow Lyse/Fix Buffer and a BD Phosflow Perm Buffer II (BD Biosciences) according to the manufacturer’s instructions. Cells were stained with FITC-Ki67 antibody (#11-5698-82; Thermo Fisher Scientific) at room temperature for 30 min and then with 1 μg/mL 7-AAD (Sigma-Aldrich). Flow cytometric analyses were performed on FACSAria IIIu (BD Biosciences).</p></sec><sec id="s4-9"><title>Cell culture</title><p>For growth assays, sorted CD34<sup>-</sup>CD150<sup>+</sup>LSK HSCs were cultured in S-Clone SF-O3 (Sanko Junyaku) supplemented with 0.1% BSA (093001; STEMCELL Technologies), 50 μM 2-ME (Sigma-Aldrich) and 1% penicillin/streptomycin/glutamine (Gibco). 20 ng/mL of recombinant mouse SCF (579706; BioLegend) and recombinant human TPO (763706; BioLegend) for HSC culture conditions and 10 ng/mL of SCF, TPO, recombinant mouse IL-3 (575506; BioLegend), and recombinant murine GM-CSF (315-03; PeproTech) for myeloid culture condition-1 were added to cultures. In the case of myeloid culture condition-2, sorted CD150<sup>+</sup>CD48<sup>-</sup>CD135<sup>-</sup>CD34<sup>-</sup>LSK HSCs, LSK cells, and GMPs were cultured in IMDM (Gibco) supplemented with 5% FBS, 50 μM 2-ME (Sigma-Aldrich), 1% penicillin/streptomycin/glutamine (Gibco), 1 mM sodium pyruvate (Gibco), and 0.1 mM MEM Non-Essential Amino Acids solution (Gibco). 25 ng/mL of SCF, TPO, recombinant human Flt3L (300-19; PeproTech) and recombinant murine IL-11 (220-11; PeproTech) and 10 ng/mL of IL-3 and GM-CSF were added to cultures.</p><p>For replating assays, LSK cells were plated in methylcellulose medium (Methocult M3234; STEMCELL Technologies) containing 20 ng/mL of SCF, TPO, IL-3, and GM-CSF.</p></sec><sec id="s4-10"><title>Retroviral vector and virus production</title><p>Full-length <italic>Pcgf1</italic> and <italic>Bmi1</italic> cDNA tagged with a 3×Flag at the N-terminus was subcloned into the retroviral vector pGCDNsam-IRES-EGFP. Full-length <italic>Hoxa9</italic> cDNA was subcloned into the retroviral vector pMYs-IRES-mCherry. A recombinant retrovirus was generated by a 293gpg packaging cell line. The virus in supernatants of 293gpg cells was concentrated by centrifugation at 6000 × <italic>g</italic> for 16 hr.</p></sec><sec id="s4-11"><title>Immunofluorescence imaging of bone marrow and spleen sections</title><p>Isolated mouse femurs were immediately placed in ice-cold 2% paraformaldehyde solution (PFA/PBS) and fixed under gentle agitation for 16 hr. The samples were then incubated in 15 and 30% sucrose for cryoprotection overnight. Samples were embedded in O.C.T. (Sakura) and frozen in cooled hexane. The 7 μm frozen sections were generated with a cryostat (Cryostar NX70, Thermo Scientific) using Kawamoto’s tape method (<xref ref-type="bibr" rid="bib27">Kawamoto, 2003</xref>). Sections on slide glasses were blocked with staining buffer (10% normal donkey serum in TBS) and an Avidin/Biotin Blocking Kit (VECTOR), then stained with biotinylated anti-lineage antibody cocktail and anti-c-Kit antibody (#AF 1356; R&amp;D Systems), or anti-FcγR-Alexa Fluor 647 (#101314; BioLegend) in staining buffer overnight at 4℃. For secondary staining, sections were incubated with streptavidin-Alexa Fluor 488 (#S11223; Invitrogen) and donkey anti-goat Alexa Fluor 555 (#A21432; Invitrogen) antibody for 3 hr at room temperature. Finally, sections were incubated with 1 μg/mL DAPI/TBS for 10 min and mounted with ProLong Glass Antifade Mountant (Thermo Scientific). Images of sections were captured on a confocal microscope (Dragonfly, Andor, or A1Rsi, Nikon) and processed using Fiji. ImageJ was used for image quantification.</p></sec><sec id="s4-12"><title>Immunofluorescence imaging of purified GMPs</title><p>GMPs were sorted directly onto glass slides using BD AriaIIIu. The cells were washed three times with PBS for 5 min between each staining step. Cells were fixed with 4% PFA for 15 min, permeabilized with 0.1% Triton X-100 for 10 min, and then blocked with 3% BSA for 1 hr at room temperature. The cells were then incubated with rabbit anti-mouse β-catenin (#9582S; Cell Signaling) primary antibody at 4°C overnight. The cells were then stained with anti-rabbit AF488A (#20015; Biotium) secondary antibody for 2 hr at room temperature. After staining with 1 μg/mL DAPI/PBS for 5 min, the cells were mounted with ProLong Glass Antifade Mountant (Thermo Fisher). DragonFly (Andor, ×40 objective) was used for image acquisition.</p></sec><sec id="s4-13"><title>Bulk RNA-seq and data processing</title><p>Total RNAs were extracted from 1000 to 5000 cells using an RNeasy Plus Micro Kit (QIAGEN) and cDNAs were synthesized using a SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Clontech) according to the manufacturer’s instructions. The ds-cDNAs were fragmented using S220 or M220 Focused-ultrasonicator (Covaris), then cDNA libraries were generated using a NEBNext Ultra DNA Library Prep Kit (New England BioLabs) according to the manufacturer’s instructions. Sequencing was performed using HiSeq1500 or HiSeq2500 (Illumina) with a single-read sequencing length of 60 bp. TopHat2 (version 2.0.13; with default parameters) was used to map the reads to the reference genome (UCSC/mm10) with annotation data from iGenomes (Illumina). Levels of gene expression were quantified using Cuffdiff (Cufflinks version 2.2.1; with default parameters). Significant expression differences were detected edgeR (version 3.14; with default parameters), with raw counts generated from String Tie. The super-computing resource was provided by the Human Genome Center, the Institute of Medical Science, the University of Tokyo (<ext-link ext-link-type="uri" xlink:href="http://sc.hgc.jp/shirokane.html">http://sc.hgc.jp/shirokane.html</ext-link>). The enrichment analyses were performed using g:Profiler tool.</p></sec><sec id="s4-14"><title>Single-cell RNA-seq and data processing</title><p>Control (1.2 × 10<sup>4</sup>) and <italic>Pcgf1<sup>Δ/Δ</sup></italic> (1.2 × 10<sup>4</sup>) LK cells were collected for single-cell RNA-seq. mRNA were isolated and libraries were prepared according to Chromium Next GEM Single Cell 3ʹ Reagent Kits v3.1 (10X Genomics). Raw data files (Base call files) were demultiplexed into fastq files using Cell Ranger with mkfastq command. Then, ‘cellranger count’ command was used for feature counts, barcode counts with reference ‘refdata-gex-mm10-2020-A.’ Filtered_feature_bc_matrix included 6565 control LK cells and 7651 <italic>Pcgf1<sup>Δ/Δ</sup></italic> LK cells. We subsampled 6565 cells from 7651 <italic>Pcgf1<sup>Δ/Δ</sup></italic> LK cells to adjust cell numbers between <italic>Pcgf1<sup>Δ/Δ</sup></italic> and control LK. Subsequent analyses were performed using Seurat 4.1.0. Quality filtering for each feature and cell was conducted based on these criteria (min.cells = 3 &amp; min.features = 200 &amp; nFeature_RNA &gt;200 &amp; nFeature_RNA &lt;10000 &amp; percent.mt &lt;5). After quality filtering, 6171 control LKs and 6198 KO LKs were used for further analysis. Feature counts are log-normalized with the function of ‘NormalizeData.’ 2000 highly variable features are selected for PCA. PC 1–10 components are used for UMAP and graph-based clustering with the functions of FindNeighbors(object, reduction = &quot;pca&quot;, dims = 1:15) and FindClusters(object, resolution = 0.28). Cluster 0, 2, and 4 cells are extracted and reanalyzed with PCA. DEGs are selected with the function of ‘FindMarkers(object, min.pct=0.25)’.</p></sec><sec id="s4-15"><title>Chromatin immunoprecipitation (ChIP) assays and ChIP-sequencing</title><p>ChIP assays for histone modifications were performed as described previously (<xref ref-type="bibr" rid="bib3">Aoyama et al., 2018</xref>) using an anti-H2AK119ub1 (#8240S; Cell Signaling Technology) and an anti-H3K27me3 (#07-449; Millipore). BM LSK cells were fixed with 1% FA at 37°C for 2 min, lysed in ChIP buffer (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.5% NP-40 substitute and cOmplete proteases inhibitor cocktail) and sonicated for 5 s ×3 times by a Bioruptor (UCD-300; Cosmo Bio). Then, cells were digested with Micrococcal Nuclease at 37°C for 40 min (New England BioLabs) and added 10 mM EDTA to stop the reaction. After the addition of an equal volume of RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA pH 8.0, 1% NP-40 substitute, 0.5% sodium deoxycholate, 0.1% SDS and cOmplete proteases inhibitor cocktail), cells were sonicated again for 5 s × 10 times by a Bioruptor. After centrifugation, supernatants were immunoprecipitated at 4°C overnight with Dynabeads Sheep Anti-Rabbit IgG (Invitrogen) conjugated with each antibody. Immunoprecipitates were washed with ChIP wash buffer (10 mM Tris-HCl pH 8.0, 500 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.5% NP-40 substitute, and cOmplete proteases inhibitor cocktail) four times and TE buffer (10 mM Tris-HCl pH 8.0 and 1 mM EDTA pH 8.0) twice. Bound chromatins and 30 μL of input DNA were suspended in 95 μL and 65 μL elution buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 1% SDS, and 250 mM NaCl), respectively. After the addition of 5 μL of 5 M NaCl, the solutions were incubated at 65°C for 4 hr, treated with 25 μg/mL RNase A (Sigma-Aldrich) at 37°C for 30 min and 0.1 mg/mL proteinase K (Roche) at 50°C for 1 hr and were purified with a MinElute PCR Purification Kit (QIAGEN).</p><p>In 3×Flag-Pcgf1ChIP assay, BM LK cells were fixed with 1% FA at 25°C for 10 min, lysed in RIPA buffer, and sonicated for 11 s ×15 times by a homogenizer (NR-50M; Micro-tec Co.). After centrifugation, supernatants were immunoprecipitated at 4°C overnight with Dynabeads Sheep Anti-Mouse IgG (Invitrogen) conjugated with an anti-FLAG antibody (Sigma-Aldrich). Then, the samples were treated in the same way as ChIP assays for histone modifications.</p><p>In ChIP-qPCR assay, quantitative real-time PCR was performed with a StepOnePlus Thermal Cycler (Thermo Fisher Scientific) using SYBR Premix Ex Taq II or TB Green Premix Ex Taq II (Takara Bio). The primer sequences used are shown in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p><p>ChIP-seq libraries were prepared using a ThruPLEX DNA-seq Kit (Clontech) according to the manufacturer’s instructions. Bowtie2 (version 2.2.6; with default parameters) was used to map the reads to the reference genome (UCSC/mm10). The RPM (reads per million mapped reads) values of the sequenced reads were calculated every 1000 bp bin with a shifting size of 100 bp using bedtools. In order to visualize with Integrative Genomics Viewer (IGV) (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/igv">http://www.broadinstitute.org/igv</ext-link>), the RPM values of the immunoprecipitated samples were normalized by subtracting the RPM values of the input samples in each bin and converted to a bigwig file using wigToBigWig tool. The super-computing resource was provided by the Human Genome Center, the Institute of Medical Science, the University of Tokyo (<ext-link ext-link-type="uri" xlink:href="http://sc.hgc.jp/shirokane.html">http://sc.hgc.jp/shirokane.html</ext-link>).</p></sec><sec id="s4-16"><title>Assay for transposase accessible chromatin with high-throughput (ATAC)-sequencing</title><p>BM CD135<sup>-</sup>LSK cells (1.6–3.0 × 10<sup>4</sup>) and GMPs (3.0 × 10<sup>4</sup>) were lysed in cold lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.1% IGEPAL CA-630) on ice for 10 min. After centrifugation, nuclei pellets were resuspended with 50 μL of transposase reaction mix (25 μL Tagment DNA buffer (illumine), 2.5 μL Tagment DNA enzyme (illumine) and 22.5 μL water), incubated at 37°C for 35 min and were purified with a MinElute PCR Purification Kit (QIAGEN). After the optimization of PCR cycle number using SYBER Green I Nucleic Acid gel Stain (Takara Bio), transposed fragments were amplified using NEBNext High Fidelity 2×PCR Master mix and index primers, and were purified with a MinElute PCR Purification Kit (QIAGEN). Library DNA was sized selected (240–360 bps) with BluePippin (Sage Science). Sequencing was performed using HiSeq1500 or HiSeq2500 (Illumina) with a single-read sequencing length of 60 bp. Bowtie2 (version 2.2.6; with default parameters) was used to map reads to the reference genome (UCSC/mm10) with annotation data from iGenomes (Illumina). Reads mapped to mitochondria were removed. To ensure even processing, reads were randomly downsampled from each sample to adjust to the smallest read number of samples. MACS (version 2.1.1; with default parameters) was used to call peaks in downsampled reads. The catalogue of all peaks called in any samples was produced by merging all called peaks that overlapped by at least one base pair using bedtools. The MACS bdgcmp function was used to compute the fold enrichment over the background for all populations, and the bedtools map function was used to count fragments in the catalogue in each population. Fragment counts at each site in the catalogue were quantile normalized between samples using the PreprocessCore package in R (3.3.2). We used the Homer package with command annotatePeaks.pl using default parameters to annotate regions with promoter and distal labels and the nearest gene, and with command findMotifsGenome.pl using default parameters to identify enriched motifs, and the catalogue of all called peaks as a background.</p></sec><sec id="s4-17"><title>Quantification and statistical analysis</title><p>Statistical tests were performed using Prism version 9 (GraphPad). The significance of difference was measured by the Student’s <italic>t</italic>-test or one-way ANOVA. Data are shown as the mean ± SEM. Significance was taken at values of *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con15"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con16"><p>Resources</p></fn><fn fn-type="con" id="con17"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experiments using mice were performed in accordance with our institutional guidelines for the use of laboratory animals and approved by the Review Board for Animal Experiments of Chiba University (approval ID: 30-56) and the University of Tokyo (approval ID: PA18-03).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83004-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of gene sets for GSEA.</title></caption><media xlink:href="elife-83004-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of target genes of PRC1, PRC2, and PCGF1 and bivalent genes in LSK cells.</title></caption><media xlink:href="elife-83004-supp2-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>DNA motifs identified in ATAC peaks at proximal promoters enriched in <italic>Pcgf1</italic><sup>Δ/Δ</sup> CD135<sup>-</sup> LSK cells (Top 12 motifs).</title></caption><media xlink:href="elife-83004-supp3-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of differentially expressed genes (DEGs) in GMPs and those overlapped between &quot;5-FU day 8 vs day 0 GMPs&quot; and &quot;Control vs <italic>Pcgf1</italic><sup><italic>Δ/Δ</italic></sup> GMPs.</title></caption><media xlink:href="elife-83004-supp4-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>List of oligonucleptide and TaqMan gene expression assay materials.</title></caption><media xlink:href="elife-83004-supp5-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>RNA sequence, ChIP sequence and ATAC sequence data were deposited in the DDBJ (accession numbers DRA008518 and DRA013523).</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Polycomb repressive complex 1.1 orchestrates homeostatic and emergency hematopoiesis and restricts transformation by acting as a rheostat of myelopoiesis</data-title><source>DDBJ</source><pub-id pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/resource/sra-submission/DRA013523">DRA013523</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Non-canonical PRC1 orchestrates homeostatic and emergency hematopoiesis and restricts transformation by acting as a rheostat of myeloid differentiation</data-title><source>DDBJ</source><pub-id pub-id-type="accession" xlink:href="https://ddbj.nig.ac.jp/resource/sra-submission/DRA008518">DRA008518</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Daniel G Tenen for providing us with Cebpa mutant mice. The super-computing resource was provided by The Human Genome Center, The Institute of Medical Science, The University of Tokyo. This work was supported in part by Grants-in-Aid for Scientific Research (#19H05653, #20K08728) and Scientific Research on Innovative Area 'Replication of Non-Genomic Codes' (#19H05746) from Japanese Society for the Promotion of Science, and Moonshot (#21zf0127003h0001) and UTOPIA (JP223fa627001) projects from the Japan Agency for Medical Research and Development.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>M</given-names></name><name><surname>Pintacuda</surname><given-names>G</given-names></name><name><surname>Masui</surname><given-names>O</given-names></name><name><surname>Koseki</surname><given-names>Y</given-names></name><name><surname>Gdula</surname><given-names>M</given-names></name><name><surname>Cerase</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Mould</surname><given-names>A</given-names></name><name><surname>Innocent</surname><given-names>C</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Schermelleh</surname><given-names>L</given-names></name><name><surname>Nesterova</surname><given-names>TB</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Brockdorff</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pcgf3/5-Prc1 initiates Polycomb recruitment in X Chromosome inactivation</article-title><source>Science</source><volume>356</volume><fpage>1081</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1126/science.aal2512</pub-id><pub-id pub-id-type="pmid">28596365</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andricovich</surname><given-names>J</given-names></name><name><surname>Kai</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Foudi</surname><given-names>A</given-names></name><name><surname>Tzatsos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Histone demethylase Kdm2B regulates lineage commitment in normal and malignant Hematopoiesis</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>905</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1172/JCI84014</pub-id><pub-id pub-id-type="pmid">26808549</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>K</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Koide</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>E</given-names></name><name><surname>Mochizuki-Kashio</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Tara</surname><given-names>S</given-names></name><name><surname>Shinoda</surname><given-names>D</given-names></name><name><surname>Hiura</surname><given-names>N</given-names></name><name><surname>Nakajima-Takagi</surname><given-names>Y</given-names></name><name><surname>Sashida</surname><given-names>G</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ezh1 targets Bivalent genes to maintain self-renewing stem cells in Ezh2-insufficient myelodysplastic syndrome</article-title><source>IScience</source><volume>9</volume><fpage>161</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.isci.2018.10.008</pub-id><pub-id pub-id-type="pmid">30396150</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avellino</surname><given-names>R</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Expression and regulation of C/EBPα in normal Myelopoiesis and in malignant transformation</article-title><source>Blood</source><volume>129</volume><fpage>2083</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-09-687822</pub-id><pub-id pub-id-type="pmid">28179278</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee Mustafi</surname><given-names>S</given-names></name><name><surname>Chakraborty</surname><given-names>PK</given-names></name><name><surname>Dwivedi</surname><given-names>SKD</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><name><surname>Moxley</surname><given-names>KM</given-names></name><name><surname>Mukherjee</surname><given-names>P</given-names></name><name><surname>Bhattacharya</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bmi1, a new target of Ck2Α</article-title><source>Molecular Cancer</source><volume>16</volume><elocation-id>56</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-017-0617-8</pub-id><pub-id pub-id-type="pmid">28270146</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Kamal</surname><given-names>M</given-names></name><name><surname>Huebert</surname><given-names>DJ</given-names></name><name><surname>Cuff</surname><given-names>J</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name><name><surname>Plath</surname><given-names>K</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Wagschal</surname><given-names>A</given-names></name><name><surname>Feil</surname><given-names>R</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A Bivalent Chromatin structure marks key developmental genes in embryonic stem cells</article-title><source>Cell</source><volume>125</volume><fpage>315</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.041</pub-id><pub-id pub-id-type="pmid">16630819</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackledge</surname><given-names>NP</given-names></name><name><surname>Farcas</surname><given-names>AM</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>King</surname><given-names>HW</given-names></name><name><surname>McGouran</surname><given-names>JF</given-names></name><name><surname>Hanssen</surname><given-names>LLP</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Koseki</surname><given-names>Y</given-names></name><name><surname>Ishikura</surname><given-names>T</given-names></name><name><surname>Long</surname><given-names>HK</given-names></name><name><surname>Sheahan</surname><given-names>TW</given-names></name><name><surname>Brockdorff</surname><given-names>N</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Klose</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Variant Prc1 complex-dependent H2A Ubiquitylation drives Prc2 recruitment and Polycomb domain formation</article-title><source>Cell</source><volume>157</volume><fpage>1445</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.05.004</pub-id><pub-id pub-id-type="pmid">24856970</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackledge</surname><given-names>NP</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Klose</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeting Polycomb systems to regulate gene expression: modifications to a complex story</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>16</volume><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1038/nrm4067</pub-id><pub-id pub-id-type="pmid">26420232</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>AL</given-names></name><name><surname>Wilkinson</surname><given-names>CR</given-names></name><name><surname>Waterman</surname><given-names>SR</given-names></name><name><surname>Kok</surname><given-names>CH</given-names></name><name><surname>Salerno</surname><given-names>DG</given-names></name><name><surname>Diakiw</surname><given-names>SM</given-names></name><name><surname>Reynolds</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>HS</given-names></name><name><surname>Tsykin</surname><given-names>A</given-names></name><name><surname>Glonek</surname><given-names>GF</given-names></name><name><surname>Goodall</surname><given-names>GJ</given-names></name><name><surname>Solomon</surname><given-names>PJ</given-names></name><name><surname>Gonda</surname><given-names>TJ</given-names></name><name><surname>D’Andrea</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Genetic regulators of Myelopoiesis and Leukemic signaling identified by Gene profiling and linear modeling</article-title><source>Journal of Leukocyte Biology</source><volume>80</volume><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1189/jlb.0206112</pub-id><pub-id pub-id-type="pmid">16769770</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname><given-names>JD</given-names></name><name><surname>Corces</surname><given-names>MR</given-names></name><name><surname>Lareau</surname><given-names>CA</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Schep</surname><given-names>AN</given-names></name><name><surname>Aryee</surname><given-names>MJ</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation</article-title><source>Cell</source><volume>173</volume><fpage>1535</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.074</pub-id><pub-id pub-id-type="pmid">29706549</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busch</surname><given-names>K</given-names></name><name><surname>Klapproth</surname><given-names>K</given-names></name><name><surname>Barile</surname><given-names>M</given-names></name><name><surname>Flossdorf</surname><given-names>M</given-names></name><name><surname>Holland-Letz</surname><given-names>T</given-names></name><name><surname>Schlenner</surname><given-names>SM</given-names></name><name><surname>Reth</surname><given-names>M</given-names></name><name><surname>Höfer</surname><given-names>T</given-names></name><name><surname>Rodewald</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fundamental properties of Unperturbed Haematopoiesis from stem cells in vivo</article-title><source>Nature</source><volume>518</volume><fpage>542</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nature14242</pub-id><pub-id pub-id-type="pmid">25686605</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>Y</given-names></name><name><surname>Mizoguchi</surname><given-names>I</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>M</given-names></name><name><surname>Orii</surname><given-names>N</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Sugahara</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Owaki</surname><given-names>T</given-names></name><name><surname>Yoshimoto</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulation of Myelopoiesis by proinflammatory Cytokines in infectious diseases</article-title><source>Cellular and Molecular Life Sciences</source><volume>75</volume><fpage>1363</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1007/s00018-017-2724-5</pub-id><pub-id pub-id-type="pmid">29218601</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Alo’</surname><given-names>F</given-names></name><name><surname>Johansen</surname><given-names>LM</given-names></name><name><surname>Nelson</surname><given-names>EA</given-names></name><name><surname>Radomska</surname><given-names>HS</given-names></name><name><surname>Evans</surname><given-names>EK</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Nerlov</surname><given-names>C</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of Granulopoietic development of hematopoietic cells</article-title><source>Blood</source><volume>102</volume><fpage>3163</fpage><lpage>3171</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-02-0479</pub-id><pub-id pub-id-type="pmid">12869508</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Pooter</surname><given-names>RF</given-names></name><name><surname>Kee</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>E proteins and the regulation of early lymphocyte development</article-title><source>Immunological Reviews</source><volume>238</volume><fpage>93</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00957.x</pub-id><pub-id pub-id-type="pmid">20969587</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farcas</surname><given-names>AM</given-names></name><name><surname>Blackledge</surname><given-names>NP</given-names></name><name><surname>Sudbery</surname><given-names>I</given-names></name><name><surname>Long</surname><given-names>HK</given-names></name><name><surname>McGouran</surname><given-names>JF</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Sims</surname><given-names>D</given-names></name><name><surname>Cerase</surname><given-names>A</given-names></name><name><surname>Sheahan</surname><given-names>TW</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Brockdorff</surname><given-names>N</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>Klose</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Kdm2B links the Polycomb repressive complex 1 (Prc1) to recognition of Cpg Islands</article-title><source>eLife</source><volume>1</volume><elocation-id>e00205</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.00205</pub-id><pub-id pub-id-type="pmid">23256043</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuchi</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>F</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Goto-Koshino</surname><given-names>Y</given-names></name><name><surname>Sotomaru</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Comprehensive analysis of myeloid lineage conversion using mice expressing an inducible form of C/EBP alpha</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>3398</fpage><lpage>3410</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601199</pub-id><pub-id pub-id-type="pmid">16858416</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Bonasio</surname><given-names>R</given-names></name><name><surname>Strino</surname><given-names>F</given-names></name><name><surname>Sawai</surname><given-names>A</given-names></name><name><surname>Parisi</surname><given-names>F</given-names></name><name><surname>Kluger</surname><given-names>Y</given-names></name><name><surname>Reinberg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>PCGF Homologs, CBX proteins, and RYBP define functionally distinct Prc1 family complexes</article-title><source>Molecular Cell</source><volume>45</volume><fpage>344</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.01.002</pub-id><pub-id pub-id-type="pmid">22325352</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gery</surname><given-names>S</given-names></name><name><surname>Gombart</surname><given-names>AF</given-names></name><name><surname>Yi</surname><given-names>WS</given-names></name><name><surname>Koeffler</surname><given-names>C</given-names></name><name><surname>Hofmann</surname><given-names>WK</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Transcription profiling of C/EBP targets identifies Per2 as a Gene implicated in myeloid leukemia</article-title><source>Blood</source><volume>106</volume><fpage>2827</fpage><lpage>2836</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-01-0358</pub-id><pub-id pub-id-type="pmid">15985538</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Taranova</surname><given-names>O</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Kdm2B maintains murine embryonic stem cell status by recruiting Prc1 complex to Cpg Islands of developmental genes</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ncb2702</pub-id><pub-id pub-id-type="pmid">23502314</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hérault</surname><given-names>A</given-names></name><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Leong</surname><given-names>S</given-names></name><name><surname>Calero-Nieto</surname><given-names>FJ</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Kang</surname><given-names>YA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Chu</surname><given-names>SH</given-names></name><name><surname>Barry-Holson</surname><given-names>K</given-names></name><name><surname>Armstrong</surname><given-names>S</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Myeloid progenitor cluster formation drives emergency and Leukaemic Myelopoiesis</article-title><source>Nature</source><volume>544</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature21693</pub-id><pub-id pub-id-type="pmid">28355185</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higa</surname><given-names>KC</given-names></name><name><surname>Goodspeed</surname><given-names>A</given-names></name><name><surname>Chavez</surname><given-names>JS</given-names></name><name><surname>De Dominici</surname><given-names>M</given-names></name><name><surname>Danis</surname><given-names>E</given-names></name><name><surname>Zaberezhnyy</surname><given-names>V</given-names></name><name><surname>Rabe</surname><given-names>JL</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>DeGregori</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Chronic Interleukin-1 exposure triggers selection for Cebpa-knockout Multipotent hematopoietic Progenitors</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20200560</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20200560</pub-id><pub-id pub-id-type="pmid">33914855</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Zuzan</surname><given-names>H</given-names></name><name><surname>Spang</surname><given-names>R</given-names></name><name><surname>Leone</surname><given-names>G</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA Microarray analysis</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>4684</fpage><lpage>4699</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.14.4684-4699.2001</pub-id><pub-id pub-id-type="pmid">11416145</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isshiki</surname><given-names>Y</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Emerging role of Noncanonical Polycomb repressive complexes in normal and malignant Hematopoiesis</article-title><source>Experimental Hematology</source><volume>68</volume><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2018.10.008</pub-id><pub-id pub-id-type="pmid">30554637</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isshiki</surname><given-names>Y</given-names></name><name><surname>Nakajima-Takagi</surname><given-names>Y</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Aoyama</surname><given-names>K</given-names></name><name><surname>Rizk</surname><given-names>M</given-names></name><name><surname>Kurosawa</surname><given-names>S</given-names></name><name><surname>Saraya</surname><given-names>A</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Sakaida</surname><given-names>E</given-names></name><name><surname>Nakaseko</surname><given-names>C</given-names></name><name><surname>Yokote</surname><given-names>K</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Kdm2B in Polycomb repressive complex 1.1 functions as a tumor Suppressor in the initiation of T-cell Leukemogenesis</article-title><source>Blood Advances</source><volume>3</volume><fpage>2537</fpage><lpage>2549</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018028522</pub-id><pub-id pub-id-type="pmid">31471323</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwama</surname><given-names>A</given-names></name><name><surname>Oguro</surname><given-names>H</given-names></name><name><surname>Negishi</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Tsukui</surname><given-names>H</given-names></name><name><surname>Ema</surname><given-names>H</given-names></name><name><surname>Kamijo</surname><given-names>T</given-names></name><name><surname>Katoh-Fukui</surname><given-names>Y</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>van Lohuizen</surname><given-names>M</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Enhanced self-renewal of hematopoietic stem cells mediated by the Polycomb Gene product Bmi-1</article-title><source>Immunity</source><volume>21</volume><fpage>843</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.11.004</pub-id><pub-id pub-id-type="pmid">15589172</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Polycomb repressive complexes in hematological malignancies</article-title><source>Blood</source><volume>130</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-02-739490</pub-id><pub-id pub-id-type="pmid">28483764</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Use of a new adhesive film for the preparation of multi-purpose fresh-frozen sections from hard tissues, whole-animals, insects and plants</article-title><source>Archives of Histology and Cytology</source><volume>66</volume><fpage>123</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1679/aohc.66.123</pub-id><pub-id pub-id-type="pmid">12846553</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>M</given-names></name><name><surname>Koche</surname><given-names>RP</given-names></name><name><surname>Rheinbay</surname><given-names>E</given-names></name><name><surname>Mendenhall</surname><given-names>EM</given-names></name><name><surname>Endoh</surname><given-names>M</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Presser</surname><given-names>A</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Chi</surname><given-names>AS</given-names></name><name><surname>Adli</surname><given-names>M</given-names></name><name><surname>Kasif</surname><given-names>S</given-names></name><name><surname>Ptaszek</surname><given-names>LM</given-names></name><name><surname>Cowan</surname><given-names>CA</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genomewide analysis of Prc1 and Prc2 occupancy identifies two classes of Bivalent domains</article-title><source>PLOS Genetics</source><volume>4</volume><elocation-id>e1000242</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000242</pub-id><pub-id pub-id-type="pmid">18974828</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubosaki</surname><given-names>A</given-names></name><name><surname>Lindgren</surname><given-names>G</given-names></name><name><surname>Tagami</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>C</given-names></name><name><surname>Tomaru</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Arner</surname><given-names>E</given-names></name><name><surname>Forrest</surname><given-names>ARR</given-names></name><name><surname>Irvine</surname><given-names>KM</given-names></name><name><surname>Schroder</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><name><surname>Kanamori-Katayama</surname><given-names>M</given-names></name><name><surname>Rehli</surname><given-names>M</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name><name><surname>Kawai</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Hayashizaki</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The combination of Gene perturbation assay and chip-chip reveals functional direct target genes for Irf8 in THP-1 cells</article-title><source>Molecular Immunology</source><volume>47</volume><fpage>2295</fpage><lpage>2302</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2010.05.289</pub-id><pub-id pub-id-type="pmid">20573402</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Sashida</surname><given-names>G</given-names></name><name><surname>Deblasio</surname><given-names>A</given-names></name><name><surname>Harr</surname><given-names>M</given-names></name><name><surname>She</surname><given-names>QB</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>HK</given-names></name><name><surname>Di Giandomenico</surname><given-names>S</given-names></name><name><surname>Elf</surname><given-names>SE</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Miyata</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Menendez</surname><given-names>S</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name><name><surname>Hedvat</surname><given-names>CV</given-names></name><name><surname>Nimer</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Akt Phosphorylates the transcriptional Repressor Bmi1 to block its effects on the tumor-suppressing Ink4A-ARF locus</article-title><source>Science Signaling</source><volume>5</volume><elocation-id>ra77</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2003199</pub-id><pub-id pub-id-type="pmid">23092893</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loke</surname><given-names>J</given-names></name><name><surname>Chin</surname><given-names>PS</given-names></name><name><surname>Keane</surname><given-names>P</given-names></name><name><surname>Pickin</surname><given-names>A</given-names></name><name><surname>Assi</surname><given-names>SA</given-names></name><name><surname>Ptasinska</surname><given-names>A</given-names></name><name><surname>Imperato</surname><given-names>MR</given-names></name><name><surname>Cockerill</surname><given-names>PN</given-names></name><name><surname>Bonifer</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>C/EBPα Overrides epigenetic Reprogramming by Oncogenic transcription factors in acute myeloid leukemia</article-title><source>Blood Advances</source><volume>2</volume><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2017012781</pub-id><pub-id pub-id-type="pmid">29431622</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Boettcher</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Emergency Granulopoiesis</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>302</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/nri3660</pub-id><pub-id pub-id-type="pmid">24751955</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Kubagawa</surname><given-names>H</given-names></name><name><surname>Ikawa</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Kakugawa</surname><given-names>K</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Kageyama</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>MD</given-names></name><name><surname>Minato</surname><given-names>N</given-names></name><name><surname>Katsura</surname><given-names>Y</given-names></name><name><surname>Kawamoto</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Prethymic T-cell development defined by the expression of paired immunoglobulin-like receptors</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>4052</fpage><lpage>4060</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600878</pub-id><pub-id pub-id-type="pmid">16292344</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Kurotaki</surname><given-names>D</given-names></name><name><surname>Kawase</surname><given-names>W</given-names></name><name><surname>Ban</surname><given-names>T</given-names></name><name><surname>Nakabayashi</surname><given-names>J</given-names></name><name><surname>Kanzaki</surname><given-names>S</given-names></name><name><surname>Sekita</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A RUNX-CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between Dcs and monocytes</article-title><source>Nature Immunology</source><volume>22</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00871-y</pub-id><pub-id pub-id-type="pmid">33603226</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nacerddine</surname><given-names>K</given-names></name><name><surname>Beaudry</surname><given-names>JB</given-names></name><name><surname>Ginjala</surname><given-names>V</given-names></name><name><surname>Westerman</surname><given-names>B</given-names></name><name><surname>Mattiroli</surname><given-names>F</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>van der Poel</surname><given-names>H</given-names></name><name><surname>Ponz</surname><given-names>OB</given-names></name><name><surname>Pritchard</surname><given-names>C</given-names></name><name><surname>Cornelissen-Steijger</surname><given-names>P</given-names></name><name><surname>Zevenhoven</surname><given-names>J</given-names></name><name><surname>Tanger</surname><given-names>E</given-names></name><name><surname>Sixma</surname><given-names>TK</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>van Lohuizen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Akt-mediated Phosphorylation of Bmi1 modulates its Oncogenic potential, E3 Ligase activity, and DNA damage repair activity in mouse prostate cancer</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>1920</fpage><lpage>1932</lpage><pub-id pub-id-type="doi">10.1172/JCI57477</pub-id><pub-id pub-id-type="pmid">22505453</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestorowa</surname><given-names>S</given-names></name><name><surname>Hamey</surname><given-names>FK</given-names></name><name><surname>Pijuan Sala</surname><given-names>B</given-names></name><name><surname>Diamanti</surname><given-names>E</given-names></name><name><surname>Shepherd</surname><given-names>M</given-names></name><name><surname>Laurenti</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>NK</given-names></name><name><surname>Kent</surname><given-names>DG</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation</article-title><source>Blood</source><volume>128</volume><fpage>e20</fpage><lpage>e31</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-05-716480</pub-id><pub-id pub-id-type="pmid">27365425</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oguro</surname><given-names>H</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Kamijo</surname><given-names>T</given-names></name><name><surname>van Lohuizen</surname><given-names>M</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Differential impact of Ink4A and ARF on hematopoietic stem cells and their bone marrow Microenvironment in Bmi1-deficient mice</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>2247</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.1084/jem.20052477</pub-id><pub-id pub-id-type="pmid">16954369</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oguro</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Ikawa</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Kawamoto</surname><given-names>H</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Poised lineage specification in Multipotential hematopoietic stem and progenitor cells by the Polycomb protein Bmi1</article-title><source>Cell Stem Cell</source><volume>6</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.01.005</pub-id><pub-id pub-id-type="pmid">20207230</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ory</surname><given-names>DS</given-names></name><name><surname>Neugeboren</surname><given-names>BA</given-names></name><name><surname>Mulligan</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A stable human-derived packaging cell line for production of high titer Retrovirus/vesicular Stomatitis virus G Pseudotypes</article-title><source>PNAS</source><volume>93</volume><fpage>11400</fpage><lpage>11406</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.21.11400</pub-id><pub-id pub-id-type="pmid">8876147</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>I</given-names></name><name><surname>Qian</surname><given-names>D</given-names></name><name><surname>Kiel</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>MW</given-names></name><name><surname>Pihalja</surname><given-names>M</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells</article-title><source>Nature</source><volume>423</volume><fpage>302</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/nature01587</pub-id><pub-id pub-id-type="pmid">12714971</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Reynaud</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>YA</given-names></name><name><surname>Carlin</surname><given-names>D</given-names></name><name><surname>Calero-Nieto</surname><given-names>FJ</given-names></name><name><surname>Leavitt</surname><given-names>AD</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Functionally distinct Subsets of lineage-Biased Multipotent Progenitors control blood production in normal and Regenerative conditions</article-title><source>Cell Stem Cell</source><volume>17</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.05.003</pub-id><pub-id pub-id-type="pmid">26095048</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Mirantes-Barbeito</surname><given-names>C</given-names></name><name><surname>Fong</surname><given-names>S</given-names></name><name><surname>Loeffler</surname><given-names>D</given-names></name><name><surname>Kovtonyuk</surname><given-names>LV</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Lakshminarasimhan</surname><given-names>R</given-names></name><name><surname>Chin</surname><given-names>CP</given-names></name><name><surname>Techner</surname><given-names>JM</given-names></name><name><surname>Will</surname><given-names>B</given-names></name><name><surname>Nerlov</surname><given-names>C</given-names></name><name><surname>Steidl</surname><given-names>U</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chronic Interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>607</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/ncb3346</pub-id><pub-id pub-id-type="pmid">27111842</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piunti</surname><given-names>A</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The roles of Polycomb repressive complexes in mammalian development and cancer</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>22</volume><fpage>326</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00341-1</pub-id><pub-id pub-id-type="pmid">33723438</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbauer</surname><given-names>F</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Transcription factors in myeloid development: balancing differentiation with transformation</article-title><source>Nature Reviews. Immunology</source><volume>7</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nri2024</pub-id><pub-id pub-id-type="pmid">17259967</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Sedello</surname><given-names>AK</given-names></name><name><surname>Todd</surname><given-names>GP</given-names></name><name><surname>Paszkowski-Rogacz</surname><given-names>M</given-names></name><name><surname>Bird</surname><given-names>AW</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Behrens</surname><given-names>K</given-names></name><name><surname>Hubner</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Waskow</surname><given-names>C</given-names></name><name><surname>Stocking</surname><given-names>C</given-names></name><name><surname>Buchholz</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Polycomb group ring finger 1 cooperates with Runx1 in regulating differentiation and self-renewal of hematopoietic cells</article-title><source>Blood</source><volume>119</volume><fpage>4152</fpage><lpage>4161</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-09-382390</pub-id><pub-id pub-id-type="pmid">22411870</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sashida</surname><given-names>G</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Epigenetic regulation of Hematopoiesis</article-title><source>International Journal of Hematology</source><volume>96</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1007/s12185-012-1183-x</pub-id><pub-id pub-id-type="pmid">23054647</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawai</surname><given-names>CM</given-names></name><name><surname>Babovic</surname><given-names>S</given-names></name><name><surname>Upadhaya</surname><given-names>S</given-names></name><name><surname>Knapp</surname><given-names>D</given-names></name><name><surname>Lavin</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>CM</given-names></name><name><surname>Goloborodko</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Fujisaki</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Mirny</surname><given-names>LA</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Reizis</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hematopoietic stem cells are the major source of Multilineage Hematopoiesis in adult animals</article-title><source>Immunity</source><volume>45</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.007</pub-id><pub-id pub-id-type="pmid">27590115</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Säwen</surname><given-names>P</given-names></name><name><surname>Eldeeb</surname><given-names>M</given-names></name><name><surname>Erlandsson</surname><given-names>E</given-names></name><name><surname>Kristiansen</surname><given-names>TA</given-names></name><name><surname>Laterza</surname><given-names>C</given-names></name><name><surname>Kokaia</surname><given-names>Z</given-names></name><name><surname>Karlsson</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Soneji</surname><given-names>S</given-names></name><name><surname>Mandal</surname><given-names>PK</given-names></name><name><surname>Rossi</surname><given-names>DJ</given-names></name><name><surname>Bryder</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Murine Hscs contribute actively to native Hematopoiesis but with reduced differentiation capacity upon aging</article-title><source>eLife</source><volume>7</volume><elocation-id>e41258</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.41258</pub-id><pub-id pub-id-type="pmid">30561324</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinoda</surname><given-names>D</given-names></name><name><surname>Nakajima-Takagi</surname><given-names>Y</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Koide</surname><given-names>S</given-names></name><name><surname>Aoyama</surname><given-names>K</given-names></name><name><surname>Saraya</surname><given-names>A</given-names></name><name><surname>Harada</surname><given-names>H</given-names></name><name><surname>Rahmutulla</surname><given-names>B</given-names></name><name><surname>Kaneda</surname><given-names>A</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Shimoda</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Sashida</surname><given-names>G</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Insufficiency of non-Canonical Prc1 Synergizes with Jak2V617F in the development of myelofibrosis</article-title><source>Leukemia</source><volume>36</volume><fpage>452</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/s41375-021-01402-2</pub-id><pub-id pub-id-type="pmid">34497325</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shooshtarizadeh</surname><given-names>P</given-names></name><name><surname>Helness</surname><given-names>A</given-names></name><name><surname>Vadnais</surname><given-names>C</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><name><surname>Beauchemin</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Bagci</surname><given-names>H</given-names></name><name><surname>Staal</surname><given-names>FJT</given-names></name><name><surname>Coté</surname><given-names>JF</given-names></name><name><surname>Möröy</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gfi1B regulates the level of WNT/Β-Catenin signaling in hematopoietic stem cells and megakaryocytes</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1270</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09273-z</pub-id><pub-id pub-id-type="pmid">30894540</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>S</given-names></name><name><surname>Nakajima-Takagi</surname><given-names>Y</given-names></name><name><surname>Aoyama</surname><given-names>K</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Saraya</surname><given-names>A</given-names></name><name><surname>Sugishita</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Ishikura</surname><given-names>T</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Loss of Pcgf5 affects global H2A Monoubiquitination but not the function of hematopoietic stem and progenitor cells</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0154561</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0154561</pub-id><pub-id pub-id-type="pmid">27136092</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slomiany</surname><given-names>BA</given-names></name><name><surname>D’Arigo</surname><given-names>KL</given-names></name><name><surname>Kelly</surname><given-names>MM</given-names></name><name><surname>Kurtz</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>C/Ebpalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>5986</fpage><lpage>5997</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.16.5986-5997.2000</pub-id><pub-id pub-id-type="pmid">10913181</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonntag</surname><given-names>R</given-names></name><name><surname>Giebeler</surname><given-names>N</given-names></name><name><surname>Nevzorova</surname><given-names>YA</given-names></name><name><surname>Bangen</surname><given-names>JM</given-names></name><name><surname>Fahrenkamp</surname><given-names>D</given-names></name><name><surname>Lambertz</surname><given-names>D</given-names></name><name><surname>Haas</surname><given-names>U</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Gassler</surname><given-names>N</given-names></name><name><surname>Cubero</surname><given-names>FJ</given-names></name><name><surname>Müller-Newen</surname><given-names>G</given-names></name><name><surname>Abdallah</surname><given-names>AT</given-names></name><name><surname>Weiskirchen</surname><given-names>R</given-names></name><name><surname>Ticconi</surname><given-names>F</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Liedtke</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cyclin E1 and Cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma</article-title><source>PNAS</source><volume>115</volume><fpage>9282</fpage><lpage>9287</lpage><pub-id pub-id-type="doi">10.1073/pnas.1807155115</pub-id><pub-id pub-id-type="pmid">30150405</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ramos</surname><given-names>A</given-names></name><name><surname>Chapman</surname><given-names>B</given-names></name><name><surname>Johnnidis</surname><given-names>JB</given-names></name><name><surname>Le</surname><given-names>L</given-names></name><name><surname>Ho</surname><given-names>YJ</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Hofmann</surname><given-names>O</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal dynamics of native haematopoiesis</article-title><source>Nature</source><volume>514</volume><fpage>322</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nature13824</pub-id><pub-id pub-id-type="pmid">25296256</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname><given-names>N</given-names></name><name><surname>Murison</surname><given-names>A</given-names></name><name><surname>Takayanagi</surname><given-names>SI</given-names></name><name><surname>Arlidge</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Garcia-Prat</surname><given-names>L</given-names></name><name><surname>Chan-Seng-Yue</surname><given-names>M</given-names></name><name><surname>Zandi</surname><given-names>S</given-names></name><name><surname>Gan</surname><given-names>OI</given-names></name><name><surname>Boutzen</surname><given-names>H</given-names></name><name><surname>Kaufmann</surname><given-names>KB</given-names></name><name><surname>Trotman-Grant</surname><given-names>A</given-names></name><name><surname>Schoof</surname><given-names>E</given-names></name><name><surname>Kron</surname><given-names>K</given-names></name><name><surname>Díaz</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>JJY</given-names></name><name><surname>Medina</surname><given-names>T</given-names></name><name><surname>De Carvalho</surname><given-names>DD</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>Vaquerizas</surname><given-names>JM</given-names></name><name><surname>Xie</surname><given-names>SZ</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name><name><surname>Lupien</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The transition from quiescent to activated States in human hematopoietic stem cells is governed by dynamic 3D genome reorganization</article-title><source>Cell Stem Cell</source><volume>28</volume><fpage>488</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.11.001</pub-id><pub-id pub-id-type="pmid">33242413</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tara</surname><given-names>S</given-names></name><name><surname>Isshiki</surname><given-names>Y</given-names></name><name><surname>Nakajima-Takagi</surname><given-names>Y</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Aoyama</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Shinoda</surname><given-names>D</given-names></name><name><surname>Koide</surname><given-names>S</given-names></name><name><surname>Saraya</surname><given-names>A</given-names></name><name><surname>Miyagi</surname><given-names>S</given-names></name><name><surname>Manabe</surname><given-names>I</given-names></name><name><surname>Matsui</surname><given-names>H</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Bardwell</surname><given-names>VJ</given-names></name><name><surname>Iwama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>Bcor</italic> insufficiency promotes initiation and progression of myelodysplastic syndrome</article-title><source>Blood</source><volume>132</volume><fpage>2470</fpage><lpage>2483</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-01-827964</pub-id><pub-id pub-id-type="pmid">30228234</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trumpp</surname><given-names>A</given-names></name><name><surname>Essers</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Awakening dormant haematopoietic stem cells</article-title><source>Nature Reviews. Immunology</source><volume>10</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/nri2726</pub-id><pub-id pub-id-type="pmid">20182459</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voncken</surname><given-names>JW</given-names></name><name><surname>Niessen</surname><given-names>H</given-names></name><name><surname>Neufeld</surname><given-names>B</given-names></name><name><surname>Rennefahrt</surname><given-names>U</given-names></name><name><surname>Dahlmans</surname><given-names>V</given-names></name><name><surname>Kubben</surname><given-names>N</given-names></name><name><surname>Holzer</surname><given-names>B</given-names></name><name><surname>Ludwig</surname><given-names>S</given-names></name><name><surname>Rapp</surname><given-names>UR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>MAPKAP kinase 3Pk Phosphorylates and regulates Chromatin Association of the Polycomb group protein Bmi1</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>5178</fpage><lpage>5187</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407155200</pub-id><pub-id pub-id-type="pmid">15563468</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>JL</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kassis</surname><given-names>JA</given-names></name><name><surname>Jones</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hierarchical recruitment of Polycomb group silencing complexes</article-title><source>Molecular Cell</source><volume>14</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.05.009</pub-id><pub-id pub-id-type="pmid">15175158</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Krivtsov</surname><given-names>AV</given-names></name><name><surname>Sinha</surname><given-names>AU</given-names></name><name><surname>North</surname><given-names>TE</given-names></name><name><surname>Goessling</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The WNT/beta-Catenin pathway is required for the development of leukemia stem cells in AML</article-title><source>Science</source><volume>327</volume><fpage>1650</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1126/science.1186624</pub-id><pub-id pub-id-type="pmid">20339075</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><name><surname>Graf</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Stepwise reprogramming of B cells into macrophages</article-title><source>Cell</source><volume>117</volume><fpage>663</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(04)00419-2</pub-id><pub-id pub-id-type="pmid">15163413</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Amabile</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Staber</surname><given-names>PB</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Levantini</surname><given-names>E</given-names></name><name><surname>Alberich-Jordà</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kawasaki</surname><given-names>A</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>C/Ebpa controls acquisition and maintenance of adult haematopoietic stem cell Quiescence</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/ncb2698</pub-id><pub-id pub-id-type="pmid">23502316</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>DE</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>ND</given-names></name><name><surname>Hetherington</surname><given-names>CJ</given-names></name><name><surname>Darlington</surname><given-names>GJ</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice</article-title><source>PNAS</source><volume>94</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.2.569</pub-id><pub-id pub-id-type="pmid">9012825</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Iwasaki-Arai</surname><given-names>J</given-names></name><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Fenyus</surname><given-names>ML</given-names></name><name><surname>Dayaram</surname><given-names>T</given-names></name><name><surname>Owens</surname><given-names>BM</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Levantini</surname><given-names>E</given-names></name><name><surname>Huettner</surname><given-names>CS</given-names></name><name><surname>Lekstrom-Himes</surname><given-names>JA</given-names></name><name><surname>Akashi</surname><given-names>K</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Enhancement of hematopoietic stem cell Repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha</article-title><source>Immunity</source><volume>21</volume><fpage>853</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.11.006</pub-id><pub-id pub-id-type="pmid">15589173</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JL</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of stress-induced Hematopoiesis</article-title><source>Current Opinion in Hematology</source><volume>22</volume><fpage>286</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1097/MOH.0000000000000149</pub-id><pub-id pub-id-type="pmid">26049748</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Wild-type mice: C57BL/6 (CD45.2)</td><td align="left" valign="bottom">Japan SLC</td><td align="left" valign="bottom">C57BL6JJmsSlc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Wild-type mice: C57BL/6 (CD45.1)</td><td align="left" valign="bottom">Sankyo-Lab Service</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Rosa26::Cre-ERT2:</italic> C57BL/6-<italic>Gt(ROSA)26Sor<sup>tm9(Cre/ESR1)Arte</sup></italic></td><td align="left" valign="bottom">TaconicArtemis GmbH</td><td align="left" valign="bottom">Model 10471</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Pcgf1<sup>fl</sup></italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Koseki H Lab</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Cebpa<sup>fl</sup></italic>: B6.129S6(CBA)-<italic>Cebpa<sup>tm1Dgt/J</sup></italic></td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">JAX: 006447</td><td align="left" valign="bottom">Daniel G. Tenen Lab</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="char" char="." valign="bottom">293gpg</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Ory et al., 1996</xref>.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">TSt-4</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib33">Masuda et al., 2005</xref>.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">TSt-4/DLL1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib33">Masuda et al., 2005</xref>.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) (rat monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 30-5931; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621652">:AB_2621652</ext-link></td><td align="left" valign="bottom">FACS (3.5 × 10<sup>–3</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-human/mouse CD11b (M1/70) (rat monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 30-0112; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621639">:AB_2621639</ext-link></td><td align="left" valign="bottom">FACS (1.8 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse TER-119 (TER-119) (rat monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 30-5921; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621651">:AB_2621651</ext-link></td><td align="left" valign="bottom">FACS (3.5 × 10<sup>–3</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-human/mouse CD45R (B220) (RA3-6B2) (rat monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 30-0452; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621644">:AB_2621644</ext-link></td><td align="left" valign="bottom">FACS (1.8 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse CD127 (IL-7Rα) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 121104; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312989">:AB_312989</ext-link></td><td align="left" valign="bottom">FACS (1.8 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse CD4 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100404; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493502">:AB_493502</ext-link></td><td align="left" valign="bottom">FACS (9 × 10<sup>–3</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse CD8a (53–6.7) (rat monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 30-0081; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621638">:AB_2621638</ext-link></td><td align="left" valign="bottom">FACS (9 × 10<sup>–3</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse Ly-6A/E (Sca-1) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108104; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_3133418">:AB_3133418</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD41a monoclonal antibody (eBioMWReg30 (MWReg30)), Biotin (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 13-0411-85; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_76348">:AB_76348</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PerCP/Cyanine5.5 Streptavidin</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 405214; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2716577">:AB_2716577</ext-link></td><td align="left" valign="bottom">FACS (5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-human/mouse CD45R (B220) (RA3-6B2) (rat monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 20-0452; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621574">:AB_2621574</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse CD117 (c-Kit) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 105812; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313221">:AB_313221</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-human/mouse CD11b (M1/70) (rat monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 20-0112; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621556">:AB_2621556</ext-link></td><td align="left" valign="bottom">FACS (5 × 10<sup>–3</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse CD4 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100412; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312697">:AB_312697</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cyanine7 anti-mouse CD4 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100526; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312727">:AB_312727</ext-link></td><td align="left" valign="bottom">FACS (5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cyanine7 anti-mouse CD8a antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100714; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312753">:AB_312753</ext-link></td><td align="left" valign="bottom">FACS (5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cyanine7 anti-mouse CD48 antibody (Armenian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103431; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621462">:AB_2621462</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cyanine7 anti-mouse CD45.2 antibody (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 109824; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_830789">:AB_830789</ext-link></td><td align="left" valign="bottom">FACS (4 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cyanine7 Streptavidin</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 405208</td><td align="left" valign="bottom">FACS (5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse Ly-6A/E (Sca-1) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108108; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313345">:AB_313345</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse/human CD11b antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101208; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312791">:AB_312791</ext-link></td><td align="left" valign="bottom">FACS (5 × 10<sup>–3</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD150 (SLAM) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 115904; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313683">:AB_313683</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD16/32 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101308; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312807">:AB_312807</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD127 (IL-7Rα) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135010; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1937251">:AB_1937251</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse Ly-6G/Ly-6C (Gr-1) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108408; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313373">:AB_313373</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–3</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD8a antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100708; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312747">:AB_312747</ext-link></td><td align="left" valign="bottom">FACS (0.2 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD43 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 143206; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11124719">:AB_11124719</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse F4/80 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 123110; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_8934865">:AB_8934865</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine7 anti-mouse Ly-6A/E (Sca-1) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108114; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493596">:AB_493596</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine7 anti-mouse CD45.1 antibody (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 110730; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1134168">:AB_1134168</ext-link></td><td align="left" valign="bottom">FACS (4 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD34 monoclonal antibody (RAM34), FITC (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 11-0341-85; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1465022">:AB_1465022</ext-link></td><td align="left" valign="bottom">FACS (0.25 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse Ly-6D antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 138606; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11203888">:AB_11203888</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse IgM antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 406506; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_315056">:AB_315056</ext-link></td><td align="left" valign="bottom">FACS (5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC anti-mouse Ly6C antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 128005; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1186134">:AB_1186134</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ki-67 monoclonal antibody (SolA15), FITC (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 11-5698-82; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11151330">:AB_11151330</ext-link></td><td align="left" valign="bottom">FACS (0.25 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 anti-mouse CD105 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 120406; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_961053">:AB_961053</ext-link></td><td align="left" valign="bottom">FACS (0.25 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">violetFluor 450 anti-mouse CD45.2 (104) (mouse monoclonal)</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 75-0454; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2621950">:AB_2621950</ext-link></td><td align="left" valign="bottom">FACS (4 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 421 anti-mouse CD135 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135314; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2562339">:AB_2562339</ext-link></td><td align="left" valign="bottom">FACS (0.25 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 421 anti-mouse CD150 (SLAM) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 115925; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10896787">:AB_10896787</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 421 anti-mouse Ly6G antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 127627; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10897944">:AB_10897944</ext-link></td><td align="left" valign="bottom">FACS (0.1 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 510 anti-mouse CD16/32 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101333; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2563692">:AB_2563692</ext-link></td><td align="left" valign="bottom">FACS (2.5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD34 monoclonal antibody (RAM34), eFluor 450 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 48-0341-82; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2043837">:AB_2043837</ext-link></td><td align="left" valign="bottom">FACS (0.25 μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 605 Streptavidin</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 405229</td><td align="left" valign="bottom">FACS (5 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">V500 mouse anti-mouse CD45.2 (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 562129; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10897142">:AB_10897142</ext-link></td><td align="left" valign="bottom">FACS (4 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BV510 Mouse Anti-Mouse CD45.1 (mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 565278; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2739150">:AB_2739150</ext-link></td><td align="left" valign="bottom">FACS (4 × 10<sup>–2</sup> μL/1 × 10<sup>6</sup> cell)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ubiquityl-Histone H2A (Lys119) (D27C4) XP rabbit mAb (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 8240S; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10891618">:AB_10891618</ext-link></td><td align="left" valign="bottom">ChIP (2 μg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-trimethyl-Histone H3 (Lys27) antibody (rabbit polyclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# 07-449; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_310624">:AB_310624</ext-link></td><td align="left" valign="bottom">ChIP (2 μg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Monoclonal anti-FLAG M2, antibody produced in mouse (mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# F1084</td><td align="left" valign="bottom">ChIP (2 μg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">β-Catenin (6B3) rabbit mAb (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9582S; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_823447">:AB_823447</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Human/mouse CD117/c-kit antibody (goat polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# AF1356; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_354750">:AB_354750</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD41a monoclonal antibody (eBioMWReg30 (MWReg30)), Biotin (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 13-0411-85; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_763489">:AB_763489</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647 anti-mouse CD16/32 antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101314; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2278396">:AB_2278396</ext-link></td><td align="left" valign="bottom">IF (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse Ly-6A/E (Sca-1) antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108104; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313341">:AB_313341</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Streptavidin, Alexa Fluor 488 conjugate</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# S11223</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-rabbit IgG (H+L), highly cross-adsorbed antibody, CF488A conjugated (donkey polyclonal)</td><td align="left" valign="bottom">Biotium</td><td align="left" valign="bottom">Cat# 20015; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10559669">AB_10559669</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-goat IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 555 (donkey polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A-21432; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535853">AB_2535853</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-goat IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 568 (donkey polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A-11057; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534104">AB_2534104</ext-link></td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer pairs for genotyping</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer pairs for qPCR</td><td align="left" valign="bottom">Universal ProbeLibrary Assay Design Center (Roche)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primer pairs for ChIP-qPCR</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Micrococcal Nuclease</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">M0247S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">RNase A</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">R6513</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Proteinase K</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">3115852001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant mouse IL-7 (carrier-free)</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">577802</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant mouse SCF (carrier-free)</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">579706</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human TPO (carrier-free)</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">763706</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant mouse IL-3 (carrier-free)</td><td align="left" valign="bottom">BioLegend</td><td align="char" char="." valign="bottom">575506</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant murine GM-CSF</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="ndash" valign="bottom">315-03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human Flt3-ligand</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="ndash" valign="bottom">300-19</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant murine IL-11</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="ndash" valign="bottom">220-11</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Micro Plus Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="char" char="." valign="bottom">74034</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TRI Reagent LS</td><td align="left" valign="bottom">MOR</td><td align="left" valign="bottom">TS120</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SuperScript IV First-Strand Synthesis System</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">18091050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ReverTra Ace a-</td><td align="left" valign="bottom">TOYOBO</td><td align="left" valign="bottom">FSQ-301</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">FastStart Universal Probe Master</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">4914058001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Methocult M3234</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="char" char="." valign="bottom">03234</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BD Phosflow Lyse/Fix Buffer</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">558049</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BD Phosflow Perm Buffer II</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">558052</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TB Green Premix Ex Taq II</td><td align="left" valign="bottom">Takara Bio</td><td align="left" valign="bottom">RR820S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">cOmplete, Mini, Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">11836170001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Dynabeads M-280 sheep anti-rabbit IgG</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">11203D</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Dynabeads M-280 sheep anti-mouse IgG</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">11202D</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MinElute PCR Purification Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="char" char="." valign="bottom">28006</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SMART-Seq v4 Ultra Low Input RNA Kit</td><td align="left" valign="bottom">Clontech</td><td align="char" char="." valign="bottom">634890</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Ultra DNA Library Prep Kit</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">E7370</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ThruPLEX DNA-seq Kit</td><td align="left" valign="bottom">Clontech</td><td align="left" valign="bottom">R400428</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Tagment DNA buffer</td><td align="left" valign="bottom">Illumina</td><td align="char" char="." valign="bottom">15027866</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Tagment DNA enzyme</td><td align="left" valign="bottom">Illumina</td><td align="char" char="." valign="bottom">15027865</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SYBER Green I Nucleic Acid gel Stain</td><td align="left" valign="bottom">Takara Bio</td><td align="char" char="." valign="bottom">5761A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext High Fidelity 2x PCR Master mix</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">M0541S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Chromium Next GEM Single Cell 3ʹ Reagent Kits v3.1</td><td align="left" valign="bottom">10X Genomics</td><td align="char" char="." valign="bottom">1000269</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">O.T.C Compound</td><td align="left" valign="bottom">Sakura</td><td align="left" valign="bottom">D3571</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ProLong Glass Antifade Mountant</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">P36982</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Avidin/Biotin Blocking Kit</td><td align="left" valign="bottom">VECTOR</td><td align="left" valign="bottom">SP-2001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">T5648</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">4-Hydroxytamoxifen</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">H7904</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Corn oil</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C8267</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Propidium iodide</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P4170</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="hyphen" valign="bottom">7-AAD</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A9400</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-Mercaptoethanol (2-ME)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">M3148</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Formaldehyde solution (FA)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">F8775</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IGEPAL CA-630</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">I8896</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium pyrubate</td><td align="left" valign="bottom">Thermo Scientific</td><td align="char" char="." valign="bottom">11360070</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">D3571</td><td align="left" valign="bottom">1 μg/mL</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pierce 16% formaldehyde (w/v), methanol-free</td><td align="left" valign="bottom">Thermo Scientific</td><td align="char" char="." valign="bottom">28906</td><td align="char" char="." valign="bottom">8%</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">5-fluorouracil (5-FU)</td><td align="left" valign="bottom">Kyowa KIRIN</td><td align="char" char="hyphen" valign="bottom">5-FU 250 mg</td><td align="left" valign="bottom">3.75 mg per 25 g body weight mouse</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 9</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td></tr><tr><td align="left" valign="bottom">software, algorithm</td><td align="left" valign="bottom">L-Calc</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.stemcell.com/l-calc-software.html">https://www.stemcell.com/l-calc-software.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Gene set enrichment analysis</td><td align="left" valign="bottom">Broad Institute</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/index.jsp">http://software.broadinstitute.org/gsea/index.jsp</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">g:Profiler</td><td align="left" valign="bottom">Raudvere et al.,<break/>2019.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://biit.cs.ut.ee/gprofiler/">https://biit.cs.ut.ee/gprofiler/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Integrate Genomics Viewer v2.4.4</td><td align="left" valign="bottom">Broad Institute</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://software.broadinstitute.org/software/igv/">https://software.broadinstitute.org/software/igv/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib49">Schindelin et al., 2012</xref>.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://fiji.sc">https://fiji.sc</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">National Institutes of Health</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/index.html">https://imagej.nih.gov/ij/index.html</ext-link></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Normal donkey serum</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="char" char="hyphen" valign="bottom">017-000-121</td><td align="left" valign="bottom">Blocking reagent for immunostaining</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S-Clone SF-O3</td><td align="left" valign="bottom">EIDIA Co., Ltd</td><td align="char" char="." valign="bottom">1303</td><td align="left" valign="bottom">Medium for cell cluture</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">10% bovine serum albumin in Iscove’s MDM</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="char" char="." valign="bottom">09300</td><td align="left" valign="bottom">Supplement for cell cluture</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83004.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.07.507016" link-type="continued-by" xlink:href="https://sciety.org/articles/10.1101/2022.09.07.507016"/></front-stub><body><p>The authors present a manuscript aiming to understand the mechanism(s) underlying myeloid bias in HSCs, specifically focused on the role of Pcgf1, and therefore PRC1.1, in the regulation of hematopoiesis. The current study demonstrates that conditional deletion of Pcgf1 in HSCs causes a lineage switch from lymphoid to myeloid fates and that a key mechanism for this lineage switch is regulation of the H2AK119ub1 chromatin mark, leading to de-repression of CEBPalpha, a key transcription factor that promotes myeloid cell fate. This important work is of interest to the community of researchers interested in myeloid differentiation, lineage fate decisions in hematopoietic stem cells, and the molecular mechanisms that contribute to the initiation of myeloid malignancies. The methods are rigorous and the results convincingly support the authors' conclusions.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83004.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Walkley</surname><given-names>Carl R</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02k3cxs74</institution-id><institution>St. Vincent's Institute of Medical Research</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/10.1101/2022.09.07.507016">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.09.07.507016v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Polycomb repressive complex 1.1 coordinates homeostatic and emergency myelopoiesis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Carl R Walkley (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>The authors present a manuscript aiming to understand the mechanism(s) underlying myeloid bias in HSCs, specifically focused on the role of Pcgf1, and therefore PRC1.1, in the regulation of hematopoiesis. This work is of interest to the community of researchers interested in myeloid differentiation, lineage fate decisions in HSCs, and the molecular mechanisms that contribute to the initiation of myeloid malignancies. This work also is of novel significance for translational purposes and could lead to the design of better therapeutics for myeloid malignancies, in the least the utility of the novel mouse model presented in this work. The current study demonstrates that conditional deletion of Pcgf1 in HSCs causes a lineage switch from lymphoid to myeloid fates and that a key mechanism for this lineage switch is regulation of the H2AK119ub1 chromatin mark, leading to de-repression of CEBPalpha, a key transcription factor that promotes myeloid cell fate. The authors also demonstrate that deletion of Pcgf1 in HSCs can also lead to deregulated myelopoiesis, leading to a lethal MPN in a subset of animals, implicating Pcgf1 as a critical regulator of emergency myelopoiesis with the potential to prevent malignant transformation of myeloid progenitors.</p><p>The reviewers found significant merit in the work both technically and conceptually. However, the evaluation identified weaknesses that prevent the publication of this work in the present form. The main shortcomings of the presented work include:</p><p>1) Lack of clarity on whether the KO findings result in a normal but excessive myeloid differentiation, or from a myeloid skew with a block in the maturation of the mature myeloid cells;</p><p>2) Need for further delineation of the subtypes of mature myeloid cells in vivo;</p><p>3) Provide in vivo data to support the in vitro evidence that restoring CEBPa rescues the myeloid bias in the Pcgf1 KO HSPCs.</p><p>A complete list of reviewer comments can be found below.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. The authors show that HoxA9 overexpression is associated with the activation of b-catenin, but the mechanism for this is unclear. Is HoxA9 a direct transcriptional activator of b-catenin? If not, can the authors speculate about a mechanism for the increase in β-catenin activation?</p><p>2. Is this really &quot;emergency myelopoiesis&quot;, or is it pathologic myelopoiesis? The authors state that &quot;the production of circulating myeloid cells was not enhanced&quot;. Is that because there is also a differentiation block? Addressing the question in of whether there is an expansion of undifferentiated cells would help to make this distinction. In Figure 6, if there is an increase in self-renewing GMPs in Pcgf1 KO mice with increased HoxA9 expression, why do the mice develop MPN and not AML? Is there any differentiation block along with the myeloid expansion? What happens to c-kit expression? Is this disease transplantable? It would also be helpful to see some high-power cytospins of the bone marrow or spleens of mice with MPN, to better assess the differentiation status.</p><p>3. It is suggested that Figure S6H should be in the last main figure, as it is a really helpful summary of the roles of PRC 1.1 in hematopoiesis.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Specific comments:</p><p>1. The work clearly shows a myeloid bias in hematopoiesis. It is not clear from the data as presented whether this is resulting in a normal but excessive myeloid differentiation, or from a myeloid skew with a block in the maturation of the mature myeloid cells. This is an important difference and would be important to understand. The present data demonstrate that the mice accumulate GMP and myeloid progenitors, but they also develop MPN and myeloid malignant/pre-malignant states. An alternative interpretation could be that the mature myeloid cells are not differentiating normally and that this is leading to excessive myeloid production to try to generate a functionally competent myeloid population for host defence.</p><p>2. The authors should more clearly describe the mature myeloid cells in the animals (across PB, BM, Spleen) and it would be useful to provide FACS plots of Mac-1/Gr-1 profiles (+/- F4/80, Ly6C/G).</p><p>3. The authors describe myeloid cells in the figure legends as &quot;Mac-1+ and/or Gr-1+ myeloid cells&quot; positive cells – please be more specific and define the populations. This applies throughout the manuscript and assays.</p><p>4. In the data in Figure 2E, can the authors provide qPCR or similar levels of Cebpa in the different genotypes. Is it demonstrated that germ-line heterozygous Cebpa would cause a reduction in the expression of Cebpa?</p><p>5. Did the authors age any mice post-5-FU to determine if this was sufficient to predispose to MPN generation or induce a more pronounced block in myeloid maturation?</p><p>6. The Hoxa9 reexpression studies in Figure 5G – This doesn't appear to have a WT control. The overexpression of Hoxa9 may be expected to have the same effect in a WT cell as that displayed (I am assuming this is a Pcgf1 deficient cell but this isn't completely clear to me from the text or legend).</p><p>7. Include an n for sick mice in Figure 6 (25 in total aged but how many got what diagnosis). Related to this, but potentially beyond the scope, is the disease transplantable?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Line 127: KO mice have mild anemia and leukopenia. Figure S2A is the only data associated with this statement – please show neutrophil, monocyte, and lymphocyte counts separately.</p><p>Figure 1I: Green/Red bar plotting could be problematic for people with color blindness. The labeling of the HSPC populations underneath the genotypes is poorly aligned – which adds to the confusion. Because the bars are stacked with multiple colors, the statistical significance is indicated for the total or specific colored portion?</p><p>How does PCGF1 non-cell autonomously control hematopoiesis? What % of Pcgf1Δ/Δ cells is needed to achieve this non-cell autonomous inhibition? This seems to be a potent aspect of regulation – some discussion would be helpful.</p><p>Line 167 and 169, &quot;… cells display slower growth under HSPC expanding condition&quot; and &quot;better growth&quot;. The word &quot;growth&quot; in these sentences is more accurate to be replaced by &quot;population doubling&quot;.</p><p>S5A is never referenced in the text. S5B, middle plot. Significance is indicated by a star in the B cell portion of the stacked bars. This is for comparing which samples/cell types, as multiple ways of comparison can be made.</p><p>Figure 2D/E provided in vitro results for restoring CEBPa in rescuing the myeloid bias in the Pcgf1Δ/Δ HSPCs. Support this claim with in vivo results.</p><p>Line 242 refers to Figure S3D: there is no panel D in Figure S3.</p><p>Line 311 Figure 3D – this should have been 3G, if I understood correctly. If I did not understand correctly, then Figure 3G is never cited. This is so terribly confusing!</p><p>Figure 3I – so poorly aligned/labelled.</p><p>Line 320-322 &quot;Moreover, ATAC-seq analyses also revealed trend toward enrichment of ATAC peaks containing CEBP motif in Pcgf1Δ/Δ HSPCs compared to the control, suggesting that chromatin regions containing CEBP motif tended to open in Pcgf1Δ/Δ HSPCs (Figure 3I).&quot; The figure supporting this claim seems to have &quot;p=0.3&quot;. Such a p-value is &quot;ns&quot; everywhere else. Why is it different here? As far as this reviewer can gather, the only significant difference in this figure is between control LSK and control GMP. Therefore, these results cannot and should not be cited as evidence to support &quot;chromatin regions containing CEBP motif tended to open in HSPCs (Figure 3I).&quot; Authors should remove any misleading claim based on this strenuous comparison.</p><p>Figure 4A. Can the difference in cluster GMPs be quantified?</p><p>Line 412-413 figure legend for Figure 4C: &quot;Each symbol is derived from an individual culture&quot;. This is supposed to be from in vivo experiments? No statistical significance indicated?</p><p>Figure 5B,5G/H, states that HSC cultures produced GMPs. This statement is misleading and contributes to the over-interpretation of the results. To the best that this data can support, perhaps it is fair to say cells expressing immunophenotypic GMP markers are produced. The authors interpreted the difference in myeloid culture condition 1 and 2 being the different responses of HSC and GMP toward the loss of Pcgf1. However, it is equally possible that the different growth factors (type and concentrations) caused the differential response between the control and Pcgf1Δ/Δ cells. The authors need to culture HSC and GMP in both myeloid culture condition 1 and 2 to justify their claims.</p><p>Figure 5D. The images are missing the labels of genotypes.</p><p>Figure 5E legend says the samples are the GMPs from HSC cultures in 5B. Were these &quot;GMPs&quot; sorted? Please specify. Why are the day 16 control &quot;GMPs&quot; missing?</p><p>Figure 5F. What samples are being compared by RNA-seq? This reviewer is guessing the same samples shown in Figure 5E. If so, it begs the same question as to why are the day 16 control &quot;GMPs&quot; missing, and why are the day 0 Pcgf1Δ/Δ GMPs missing.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83004.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>The authors present a manuscript aiming to understand the mechanism(s) underlying myeloid bias in HSCs, specifically focused on the role of Pcgf1, and therefore PRC1.1, in the regulation of hematopoiesis. This work is of interest to the community of researchers interested in myeloid differentiation, lineage fate decisions in HSCs, and the molecular mechanisms that contribute to the initiation of myeloid malignancies. This work also is of novel significance for translational purposes and could lead to the design of better therapeutics for myeloid malignancies, in the least the utility of the novel mouse model presented in this work. The current study demonstrates that conditional deletion of Pcgf1 in HSCs causes a lineage switch from lymphoid to myeloid fates and that a key mechanism for this lineage switch is regulation of the H2AK119ub1 chromatin mark, leading to de-repression of CEBPalpha, a key transcription factor that promotes myeloid cell fate. The authors also demonstrate that deletion of Pcgf1 in HSCs can also lead to deregulated myelopoiesis, leading to a lethal MPN in a subset of animals, implicating Pcgf1 as a critical regulator of emergency myelopoiesis with the potential to prevent malignant transformation of myeloid progenitors.</p><p>The reviewers found significant merit in the work both technically and conceptually. However, the evaluation identified weaknesses that prevent the publication of this work in the present form. The main shortcomings of the presented work include:</p><p>1) Lack of clarity on whether the KO findings result in a normal but excessive myeloid differentiation, or from a myeloid skew with a block in the maturation of the mature myeloid cells;</p><p>2) Need for further delineation of the subtypes of mature myeloid cells in vivo;</p><p>3) Provide in vivo data to support the in vitro evidence that restoring CEBPa rescues the myeloid bias in the Pcgf1 KO HSPCs.</p><p>A complete list of reviewer comments can be found below.</p></disp-quote><p>Thank you for your suggestions. In response to the points raised above, we performed additional experiments, presented data in new figures, and revised the main text. Among the 3 main shortcomings of the presented work you pointed out, we clearly addressed the points 1 and 2. Regarding the point 3, we tried competitive BM transplantation assays using conditional <italic>Pcgf1</italic> KO, <italic>Cebpa</italic> KO, and compound mice to rescue dysregulated differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs. However, we found that the deletion efficiency of <italic>Cebpa</italic> was poor in vivo using tamoxifen, while it is quite efficient in vitro using 4-hydroxytamoxifen. The data we obtained was hard to interpret. We would like to address this issue in our future experiments using different approaches. Details are described in the following responses to the reviewers.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. The authors show that HoxA9 overexpression is associated with the activation of b-catenin, but the mechanism for this is unclear. Is HoxA9 a direct transcriptional activator of b-catenin? If not, can the authors speculate about a mechanism for the increase in β-catenin activation?</p></disp-quote><p>We examined the promoter region of the <italic>Ctnnb1</italic> gene by JASPER database (https://jaspar.genereg.net/) and found at least one predicted sequence for HoxA9 binding (CTTATAAATCG) (data not shown). We performed qPCR analysis using <italic>HoxA9</italic> overexpression samples at day 12 of culture, in which nuclear localization of β-catenin was observed upon <italic>HoxA9</italic> overexpression (Figure 5H). <italic>Ctnnb1</italic> gene expression was slightly but significantly upregulated in <italic>HoxA9</italic> overexpression samples compared to mock control (Figure 5—figure supplement 1C). These results raise the possibility that HoxA9 is a direct transcriptional activator of the <italic>Ctnnb1</italic> gene, but this warrants further analysis. We described these points in lines 385-392.</p><disp-quote content-type="editor-comment"><p>2. Is this really &quot;emergency myelopoiesis&quot;, or is it pathologic myelopoiesis? The authors state that &quot;the production of circulating myeloid cells was not enhanced&quot;. Is that because there is also a differentiation block? Addressing the question in of whether there is an expansion of undifferentiated cells would help to make this distinction. In Figure 6, if there is an increase in self-renewing GMPs in Pcgf1 KO mice with increased HoxA9 expression, why do the mice develop MPN and not AML? Is there any differentiation block along with the myeloid expansion? What happens to c-kit expression? Is this disease transplantable? It would also be helpful to see some high-power cytospins of the bone marrow or spleens of mice with MPN, to better assess the differentiation status.</p></disp-quote><p>We think the reviewer’s points are very important. The data in Figure S2 (Figure 1—figure supplement 2 in revised manuscript) indicate accumulation of mature myeloid cells in Pcgf1 KO BM and spleen. To further confirm this, we performed additional FACS analyses using mature myeloid surface marker (Ly6G, Ly6C, F4/80) antibodies. The results showed that the number of mature myeloid cells expressing myeloid differentiation markers increased in Pcgf1 KO BM and spleen. Monocytes but not neutrophils or F4/80+ macrophages significantly increased in Pcgf1 KO BM while both neutrophils and monocytes significantly increased in Pcgf1 KO spleen. We replaced the flow cytometric profiles of Mac1 and Gr1 staining with those of Mac1, Ly6G, and Ly6c staining and added graphs of their absolute numbers (Figure 1—figure supplement 2C and D). These findings indicate that the expanded Pcgf1 KO GMPs can supply mature myeloid cells and do not show evident differentiation block. This notion was supported by better production of Mac-1+ mature myeloid cells by Pcgf1 KO GMPs than control GMPs in culture (Figure 5—figure supplement 1A). Even in Pcgf1 KO mice at the MPN stage, GMPs actively produced mature myeloid cells and no obvious differentiation block like AML was observed. As we discussed, the molecular machineries that drive emergency myelopoiesis are often hijacked by transformed cells (Hérault et al., 2017). It is assumed that the epigenetic status that allows GMP self-renewal was enforced over time in the absence of Pcgf1, leading to enhanced production of mature myeloid cells that mimic MPN. Indeed, we did not see accumulation of c-Kit+ leukemic blasts in BM by FACS or accumulation of leukemic blasts in BM images with higher magnification (Figure 6F). Although we haven't investigated whether the disease is transplantable or not, we would like to address this in our future experiments. We described these points in lines 131-138 and 400-405.</p><disp-quote content-type="editor-comment"><p>3. It is suggested that Figure S6H should be in the last main figure, as it is a really helpful summary of the roles of PRC 1.1 in hematopoiesis.</p></disp-quote><p>Thank you for your suggestion. We presented Figure S6H as Figure 6H.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Specific comments:</p><p>1. The work clearly shows a myeloid bias in hematopoiesis. It is not clear from the data as presented whether this is resulting in a normal but excessive myeloid differentiation, or from a myeloid skew with a block in the maturation of the mature myeloid cells. This is an important difference and would be important to understand. The present data demonstrate that the mice accumulate GMP and myeloid progenitors, but they also develop MPN and myeloid malignant/pre-malignant states. An alternative interpretation could be that the mature myeloid cells are not differentiating normally and that this is leading to excessive myeloid production to try to generate a functionally competent myeloid population for host defence.</p></disp-quote><p>We think the reviewer’s points are very important. The data in Figure S2 (Figure 1—figure supplement 2 in revised manuscript) indicate accumulation of mature myeloid cells in Pcgf1 KO BM and spleen. To further confirm this, we performed additional FACS analyses using mature myeloid surface marker (Ly6G, Ly6C, F4/80) antibodies. The results showed that the number of mature myeloid cells expressing myeloid differentiation markers increased in Pcgf1 KO BM and spleen. Monocytes but not neutrophils or F4/80+ macrophages significantly increased in Pcgf1 KO BM while both neutrophils and monocytes significantly increased in Pcgf1 KO spleen. We replaced the flow cytometric profiles of Mac1 and Gr1 staining with those of Mac1, Ly6G, and Ly6c staining and added graphs of their absolute numbers (Figure 1—figure supplement 2C and D). These findings indicate that the expanded Pcgf1 KO GMPs can supply mature myeloid cells and do not show evident differentiation block. This notion was supported by better production of Mac-1+ mature myeloid cells by Pcgf1 KO GMPs than control GMPs in culture (Figure 5—figure supplement 1A). Even in Pcgf1 KO mice at the MPN stage, GMPs actively produced mature myeloid cells and no obvious differentiation block like AML was observed. As we discussed, the molecular machineries that drive emergency myelopoiesis are often hijacked by transformed cells (Hérault et al., 2017). It is assumed that the epigenetic status that allows GMP self-renewal was enforced over time in the absence of Pcgf1, leading to enhanced production of mature myeloid cells that mimic MPN. Indeed, we did not see accumulation of c-Kit+ leukemic blasts in BM by FACS or accumulation of leukemic blasts in BM images with higher magnification (Figure 6F). We described these points in lines 131-138 and 400- 405.</p><disp-quote content-type="editor-comment"><p>2. The authors should more clearly describe the mature myeloid cells in the animals (across PB, BM, Spleen) and it would be useful to provide FACS plots of Mac-1/Gr-1 profiles (+/- F4/80, Ly6C/G).</p></disp-quote><p>Thank you for your valuable suggestion. As described in response to your point 1, we performed an additional FACS analysis and presented the results in Figure 1—figure supplement 2C and D.</p><disp-quote content-type="editor-comment"><p>3. The authors describe myeloid cells in the figure legends as &quot;Mac-1+ and/or Gr-1+ myeloid cells&quot; positive cells – please be more specific and define the populations. This applies throughout the manuscript and assays.</p></disp-quote><p>For PB analysis, we used a mixture of Mac-1 and Gr-1 antibodies with the same conjugation. So, we defined myeloid cells as those positively reacted with a mixture of Mac-1 and Gr-1 antibodies. In this case, all types of myeloid cells were included. Instead, we performed detailed profiling of BM and spleen myeloid cells using Mac-1, Ly6C and Ly6G antibodies as described above (Figure 1—figure supplement 2C and D).</p><disp-quote content-type="editor-comment"><p>4. In the data in Figure 2E, can the authors provide qPCR or similar levels of Cebpa in the different genotypes. Is it demonstrated that germ-line heterozygous Cebpa would cause a reduction in the expression of Cebpa?</p></disp-quote><p>We have added qPCR data to Figure 2E. <italic>Cebpa</italic> gene expression levels in <italic>Pcgf1<sup>Δ/Δ</sup></italic> ;<italic>Cebpa<sup>Δ/+</sup></italic> cells were significantly reduced (Figure 2E lower right).</p><disp-quote content-type="editor-comment"><p>5. Did the authors age any mice post-5-FU to determine if this was sufficient to predispose to MPN generation or induce a more pronounced block in myeloid maturation?</p></disp-quote><p>Thank you for your very interesting suggestion. We would like to test in our future experiments.</p><disp-quote content-type="editor-comment"><p>6. The Hoxa9 reexpression studies in Figure 5G – This doesn't appear to have a WT control. The overexpression of Hoxa9 may be expected to have the same effect in a WT cell as that displayed (I am assuming this is a Pcgf1 deficient cell but this isn't completely clear to me from the text or legend).</p></disp-quote><p>We apologize for the lack of clarity in our description. The experiment in Figure 5G was performed using <italic>Hoxa9</italic>-overexpressing WT LSK cells, not in Pcgf1 KO cells. This experiment was designed to test whether <italic>Hoxa9</italic> overexpression alone can maintain the immunophenotypic GMPs for a long period as in Pcgf1 KO cells.</p><disp-quote content-type="editor-comment"><p>7. Include an n for sick mice in Figure 6 (25 in total aged but how many got what diagnosis). Related to this, but potentially beyond the scope, is the disease transplantable?</p></disp-quote><p>We have indicated the number of mice per diagnosis in Figure 6A. Although we haven't investigated whether the disease is transplantable or not, we would like to address this in our future experiments.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Line 127: KO mice have mild anemia and leukopenia. Figure S2A is the only data associated with this statement – please show neutrophil, monocyte, and lymphocyte counts separately.</p></disp-quote><p>Thank you for your suggestion. We showed the lineage cell counts (myeloid/B/T) 1 and 6 months after tamoxifen injection in Figure 1—figure supplement 2B. We also analyzed myeloid cells (neutrophils, monocytes, and macrophages) more in detail in the BM and spleen and presented the data in Figure 1—figure supplement 2C and D. We described these points in lines 131-138.</p><disp-quote content-type="editor-comment"><p>Figure 1I: Green/Red bar plotting could be problematic for people with color blindness. The labeling of the HSPC populations underneath the genotypes is poorly aligned – which adds to the confusion. Because the bars are stacked with multiple colors, the statistical significance is indicated for the total or specific colored portion?</p></disp-quote><p>Thank you for your important point. We changed the bar plotting color from Green/Red to Blue/Red. We also improved the labeling of genotypes and cell populations to make it easier to understand. Statistical significance is based on the overall number of cells. We indicated this point in Figure 1I legend.</p><disp-quote content-type="editor-comment"><p>How does PCGF1 non-cell autonomously control hematopoiesis? What % of Pcgf1Δ/Δ cells is needed to achieve this non-cell autonomous inhibition? This seems to be a potent aspect of regulation – some discussion would be helpful.</p></disp-quote><p>Thank you very much for your very interesting suggestion. These findings suggest that <italic>Pcgf1<sup>Δ/Δ</sup></italic> hematopoietic cells suppress expansion of both <italic>Pcgf1<sup>Δ/Δ</sup></italic> and co-existing WT HSPCs through non- autonomous mechanisms. It is possible that accumulating <italic>Pcgf1<sup>Δ/Δ</sup></italic> mature myeloid cells produce inflammatory cytokines that are suppressive to HSPCs. We are very interested in this issue and would like to address it in our future project. We discussed this point in lines 169-173.</p><disp-quote content-type="editor-comment"><p>Line 167 and 169, &quot;… cells display slower growth under HSPC expanding condition&quot; and &quot;better growth&quot;. The word &quot;growth&quot; in these sentences is more accurate to be replaced by &quot;population doubling&quot;.</p></disp-quote><p>As the reviewer pointed out, we replaced the word &quot;growth&quot; with &quot;population doubling&quot;.</p><disp-quote content-type="editor-comment"><p>S5A is never referenced in the text. S5B, middle plot. Significance is indicated by a star in the B cell portion of the stacked bars. This is for comparing which samples/cell types, as multiple ways of comparison can be made.</p></disp-quote><p>We unintentionally missed to reference Figure S5A (Figure 2—figure supplement 1A) in revised manuscript in the text. We referred to Figure S5A in line 215. The significance shown in the Figure S5B (Figure 2—figure supplement 1B in revised manuscript) middle plot was calculated by comparing the proportion of each lineage cell of each genotype to that in GFP control. We described this point in the legend.</p><disp-quote content-type="editor-comment"><p>Figure 2D/E provided in vitro results for restoring CEBPa in rescuing the myeloid bias in the Pcgf1Δ/Δ HSPCs. Support this claim with in vivo results.</p></disp-quote><p>Thank you for your suggestion. We tried competitive BM transplantation assays using conditional <italic>Pcgf1</italic> KO, <italic>Cebpa</italic> KO, and compound mice to rescue dysregulated differentiation of <italic>Pcgf1<sup>Δ/Δ</sup></italic> HSPCs. However, we found that the deletion efficiency of <italic>Cebpa</italic> was poor in vivo using tamoxifen, while it is quite efficient in vitro using 4-hydroxytamoxifen. The data we obtained was hard to interpret. We would like to address this issue in our future experiments using different approaches.</p><disp-quote content-type="editor-comment"><p>Line 242 refers to Figure S3D: there is no panel D in Figure S3.</p></disp-quote><p>Thank you for pointing this out. We corrected Figure S3D to Figure 1D.</p><disp-quote content-type="editor-comment"><p>Line 311 Figure 3D – this should have been 3G, if I understood correctly. If I did not understand correctly, then Figure 3G is never cited. This is so terribly confusing!</p></disp-quote><p>We apologize for the incorrect description. We corrected Figure 3D to Figure 3G.</p><disp-quote content-type="editor-comment"><p>Figure 3I – so poorly aligned/labelled.</p><p>Line 320-322 &quot;Moreover, ATAC-seq analyses also revealed trend toward enrichment of ATAC peaks containing CEBP motif in Pcgf1Δ/Δ HSPCs compared to the control, suggesting that chromatin regions containing CEBP motif tended to open in Pcgf1Δ/Δ HSPCs (Figure 3I).&quot; The figure supporting this claim seems to have &quot;p=0.3&quot;. Such a p-value is &quot;ns&quot; everywhere else. Why is it different here? As far as this reviewer can gather, the only significant difference in this figure is between control LSK and control GMP. Therefore, these results cannot and should not be cited as evidence to support &quot;chromatin regions containing CEBP motif tended to open in HSPCs (Figure 3I).&quot; Authors should remove any misleading claim based on this strenuous comparison.</p></disp-quote><p>We are sorry for misleading statements. We deleted Figure 3I and related statements.</p><disp-quote content-type="editor-comment"><p>Figure 4A. Can the difference in cluster GMPs be quantified?</p></disp-quote><p>We quantified cKit<sup>+</sup>FcγR<sup>+</sup> cells (GMP clusters) using ImageJ software and presented the data in Figure 4A right panel.</p><disp-quote content-type="editor-comment"><p>Line 412-413 figure legend for Figure 4C: &quot;Each symbol is derived from an individual culture&quot;. This is supposed to be from in vivo experiments? No statistical significance indicated?</p></disp-quote><p>Thank you for pointing this mistake out. We corrected “an individual culture” to “individual mice”. We have already shown statistical significance against day 0 for each genotype. For example, in the case of total BM, statistical significance was confirmed only on day 8 for both Control and <italic>Pcgf1<sup>Δ/Δ</sup></italic>. We described these points in the legend.</p><disp-quote content-type="editor-comment"><p>Figure 5B,5G/H, states that HSC cultures produced GMPs. This statement is misleading and contributes to the over-interpretation of the results. To the best that this data can support, perhaps it is fair to say cells expressing immunophenotypic GMP markers are produced. The authors interpreted the difference in myeloid culture condition 1 and 2 being the different responses of HSC and GMP toward the loss of Pcgf1. However, it is equally possible that the different growth factors (type and concentrations) caused the differential response between the control and Pcgf1Δ/Δ cells. The authors need to culture HSC and GMP in both myeloid culture condition 1 and 2 to justify their claims.</p></disp-quote><p>Thank you for your suggestions. We changed the designation from GMP to immunophenotypic GMP. We also performed GMP culture in Figure 5A using myeloid culture condition 2, the same condition as HSCs in Figure 5B, and presented new data in Figure 5A.</p><disp-quote content-type="editor-comment"><p>Figure 5D. The images are missing the labels of genotypes.</p></disp-quote><p>These images are included simply as examples of nuclear β-Cat determination. All images are from control cells. We indicated this information in its legend.</p><disp-quote content-type="editor-comment"><p>Figure 5E legend says the samples are the GMPs from HSC cultures in 5B. Were these &quot;GMPs&quot; sorted? Please specify. Why are the day 16 control &quot;GMPs&quot; missing?</p></disp-quote><p>We sorted immunophenotypic GMPs (CD34<sup>+</sup>FcγR<sup>+</sup>c-Kit<sup>+</sup>Sca-1<sup>-</sup>Lineage<sup>-</sup>). We clarified this point in the legend. Unfortunately, control GMPs on day 16 were too few to analyze.</p><disp-quote content-type="editor-comment"><p>Figure 5F. What samples are being compared by RNA-seq? This reviewer is guessing the same samples shown in Figure 5E. If so, it begs the same question as to why are the day 16 control &quot;GMPs&quot; missing, and why are the day 0 Pcgf1Δ/Δ GMPs missing.</p></disp-quote><p>We are sorry for the lack of clarity, All samples were compared to the day 0 control GMPs. It is indicated in the upper left corner of the table. The day 16 control GMPs was too few to perform analysis. This is why we used day 0 <italic>Pcgf1<sup>Δ/Δ</sup></italic> GMPs as a reference.</p></body></sub-article></article>